TITLE PAGE  
Protocol Title : A phase II, observer -blind, randomized, controlled study to evaluate the 
immunogenicity and safety of a varicella vaccine at various potencies compared with Varivax , as 
a first dose, administered in healthy children in their second year of life  
Protocol Number : 217212 (VNS 20 -006) 
Amendment  Number : 3.[ADDRESS_348185] : Investigational varicella vaccine  
Short Title: A study on the immune response and safety of various potencies  of an 
investigational  chickenpox vaccine compared with a marketed chickenpox vaccine, given to 
healthy children 12 to 15 months of age  
Study Phase: II 
Sponsor Name : [CONTACT_285161] ([COMPANY_004])  
Legal Registered Address:  Rue de l’Institut 89, Rixensart, 1330 Belgium  
ClinicalTrials. gov Identifier : [STUDY_ID_REMOVED]  
EudraCT  Number : 2022 -001910 -21 
Date  of Original Protocol : Final Version 2: 12 July 2021  
Date of Protocol Amendment 1.0:  08 October 2021  
Date of Protocol  Amendment 2.0: 15 November  2021  
Date of Protocol  Amendment 3.0 : 18 May 2022  
 
  
1
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
Sponsor Signatory:  
 
 
I have read this protocol in its entirety and agree to conduct the study accordingly:  
 
 
 
 
 
 
Md Ahsan Habib , MBBS, MIPH  
Clinical and Epi[INVESTIGATOR_285091]’s name [CONTACT_3669] 
[CONTACT_3031].  
 
 
2
[COMPANY_003]
CONFIDENTIAL  217212 (VNS 20 -006) 
Protocol Amendment  3.[ADDRESS_348186]-2021 Yes Global  
Original Protocol  (Final Version 2)  12-Jul-2021 - - 
Amendment 3.0 ( 18-May -2022)  
This amendment is considered substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union.  
Overall Rationale for the Amendment:  
The protocol was amended primarily to reflect the expansion of the study to the countries other 
than the [LOCATION_002] of America  (US) . Outside of the US, participants will have the same 
vaccination schedule but will be co -administered Prevnar  13 only if the pneumococcal conjugate 
vaccine is recommended at 12 -15 months as per national  immunization schedule. Also, the 
storage conditions for Varivax  were updated with the country -specific details, and corrections 
were made to the temperature excursions for study vaccines. Additionally, this amendment 
conditionally allowed administration o f a second dose of Varivax  and/or Havrix  in non -US 
countries (not part of the study procedures ). 
Table [ADDRESS_348187] Important Changes in Amendment 3.0 
Section  # and Name  [CONTACT_11029]  
1.1. Synopsis  
1.3. Schedule of 
Activities  
2.1. Study Rationale  
5.1. Inclusion Criteria  Updated the text to reflect the following (in bold ; in the exact or 
similar wording):  
In this study, all participants recruited in the US will be 
co-administered with a measles, mumps and rubella vaccine ( M-M-R 
II, also called M-M-RVaxPro  in countries outside the US,  and 
hereafter designated as MMR), a hepatitis A vaccine ( Havrix ) and a 
13-valent pneumococcal conjugate vaccine ( Prevnar 13 ).
Participants recruited outside of the US  will be co -administered
with MMR, Havrix , and in some countries, with Prevnar [ADDRESS_348188] addition 
of non -US sites to 
the study and clarify 
the inclusion criteria 
applicable to the 
participants at 
non-US sites.  
To note that in some 
countries, there can 
be a different name 
[CONTACT_285162].  
1.2. Synopsis  
1.3. Schedule of At the end of the study or shortly after the study, depending on 
the vaccines’ availability, [COMPANY_004] will provide a second dose of To allow 
administration of the 
3
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Section  # and Name  [CONTACT_285163]  
2.1. Study Rationale  
 Varivax  and/or Havrix  to participants enrolled in non -US 
countries if local health departments do not routinely provide 
varicella and/or hepatitis A vaccine. Study participants who do 
not achieve the pre -specified seroresponse threshold criteria will 
be re -vaccinated with a do se of Varivax . second dose of the 
varicella or 
hepatitis  A vaccine  
(not part of study 
procedures) . 
6.2. Preparation/Handl
ing/Storage/Accounta
bility  Added the text (in bold ): 
Varivax  will be stored at −15°C to − 30°C (+5°F to − 22°F) in the 
US and other countries with frozen formulation  and at +2°C to 
+8°C (+36°F to +46°F) in the rest of the world. (Note: refrigerated 
Varivax  vaccine will be used at non -US sites, while frozen Varivax  
vaccine will be used at sites in the US  and other countries with 
frozen formulation .) To specify the 
storage conditions 
for the study vaccine 
at the US and 
non-US sites.  
Throughout the 
protocol where 
applicable  Removed  the statements implying the study will be conducted in the 
US only ; made updates regarding other countries  to the scientific 
rationale for study design; mentioned Independent Ethics 
Committee(s) as entities overseeing  the ethics conduct of the study  
besides Institutional Review Boards; men tioned the non -US-specific 
regulatory requirements the study will be performed in accordance 
with.  To reflect addition 
of non -US sites to 
the study and note 
applicable 
administrative 
changes to the 
conduct of the study.  
The detailed description of changes (i.e., added/removed text) and minor updates is provided in 
Appendix 5 . 
4
CONFIDENTIAL  217212 (VNS 20 -006) 
Protocol Amendment  3.0 
TABLE  OF CONTENTS  
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE  ................................ 3
TABLE  OF CONTENTS  ................................ ................................ ................................ ........ 5
TABLE OF TABLES ...............................................................................................................8
TABLE OF FIGURES ...........................................................................................................09
1.0 PROTOCOL SUMMARY ........................................................................................10
1.1 Synopsis ...........................................................................................................10
1.2 Schema ............................................................................................................11
1.3 Schedule of Activities .....................................................................................12
2.0 INTRODUCTION......................................................................................................1 6
2.1 Study Rationale ..............................................................................................16
2.2 Background ....................................................................................................16
2.3 Benefit/Risk Assessment ................................................................................17
2.3.1 Risk Assessment ................................................................................17
2.3.2 Risk Mitigation Strategies .................................................................1 8
2.3.3 Benefit Assessment ........................................................................... 19
2.3.4 Overall Benefit/Risk Conclusion .......................................................19
3.0 OBJECTIVES AND ENDPOINTS ..........................................................................20
4.0 STUDY DESIGN ........................................................................................................21
4.1 Overall Design ................................................................................................21
4.2 Scientific Rationale for Study Design ...........................................................24
4.2.1 Rationale for Clinical Study Population ............................................24
4.2.2 Choice of Comparator and Co-administered Vaccines .....................24
4.2.3 Rationale for Blinding .......................................................................24
4.2.4 Justification for Dose of Varicella Vaccine .......................................25
4.3 End of Study Definition .................................................................................25
5.0 STUDY POPULATION ............................................................................................26
5.1 Inclusion Criteria ...........................................................................................26
5.2 Exclusion Criteria ..........................................................................................26
5.2.1 Medical Conditions ...........................................................................26
5.2.2 Prior and Concomitant Therapy ........................................................27
5.2.3 Prior/Concurrent Clinical Study Experience .....................................27
5.2.4 Other Exclusions ...............................................................................28
5.3 Lifestyle Considerations, Activity, and Dietary Restrictions .....................28
5
CONFIDENTIAL  217212 (VNS 20 -006) 
Protocol Amendment  3.0 
5.4 Screen Failures ...............................................................................................28
5.5 Criteria for Temporary Delay for Enrollment and/or Intervention 
Administration ...............................................................................................28
6.0 STUDY INTERVENTION ........................................................................................29
6.1 Study Interventions Administered ...............................................................29
6.2 Preparation/Handling/Storage/Accountability ...........................................33
6.2.1 Minimizing Environmental Contamination with Genetically 
Modified Organisms ..........................................................................34
6.3 Measures to Minimize Bias: Randomization and Blinding........................34
6.3.1 Participant Identification ...................................................................34
6.3.2 Randomization to Study Intervention ................................................34
6.3.3 Intervention Allocation to Participants ..............................................34
6.3.4 Blinding and Unblinding ...................................................................35
6.4 Study Intervention Compliance ....................................................................36
6.5 Dose Modification ..........................................................................................36
6.6 Continuing Access to Study Intervention after the End of the 
Study................................................................................................................36
6.7 Treatment of Overdose ..................................................................................36
6.8 Concomitant Therapy ....................................................................................37
7.0 DISCONTINUATION OF STUDY TREATMENT AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL ................................................................38
7.1 Discontinuation of Study Intervention .........................................................38
7.2 Contraindications to Subsequent Study Interventions 
Administration ...............................................................................................38
7.3 Participant Discontinuation/Withdrawal from the Study .........................[ADDRESS_348189] .................................................................................46
8.3.6 Medical Device Deficiencies .............................................................46
6
CONFIDENTIAL  217212 (VNS 20 -006) 
Protocol Amendment  3.0 
8.4 Pharmacokinetics and Pharmacodynamics .................................................47
8.5 Study Procedures During Special Circumstances ......................................47
9.0 STATISTICAL CONSIDERATIONS .....................................................................49
9.1 Statistical Hypotheses ....................................................................................49
9.2 Sample Size Determination ...........................................................................49
9.3 Populations for Analyses ...............................................................................49
9.4 Statistical Analyses.........................................................................................50
9.4.1 Statistical Analysis Plan ....................................................................5 0
9.4.2 Primary Endpoint Analyses ...............................................................50
9.4.3 Secondary Endpoints Analyses .........................................................51
9.5 Interim Analysis .............................................................................................51
9.5.1 Sequence of Analyses ........................................................................51
9.5.2 Statistical Considerations for Interim Analysis .................................51
10.0  REFERENCES ...........................................................................................................52
11.0  APPENDICES ............................................................................................................53
Appendix  1 Abbreviations and the Glossary of Terms .....................................54
Appendix  2 Regulatory, Ethical, and Study Oversight Considerations ..........60
Regulatory and Ethical Considerations ............................................................60
Financial Disclosure.........................................................................................6 0
Informed Consent Process ...............................................................................61
Data Protection.................................................................................................6 1
Administrative Structure ..................................................................................62
Medical Monitor ..............................................................................................62
Dissemination of Clinical Study Data..............................................................6 2
Publication Policy ............................................................................................62
Data Quality Assurance ...................................................................................63
Source Documents ...........................................................................................64
Study and Study Center Start and Closure .......................................................64
Appendix 3 Clinical Laboratory Tests ...............................................................65
Appendix  4 Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow-up, and Reporting .....................................66
Adverse Events ................................................................................................66
Serious Adverse Events ...................................................................................67
Solicited Events ...............................................................................................67
Unsolicited Events ...........................................................................................68
COVID-19 Cases .............................................................................................68
Assessment of Intensity and Toxicity ..............................................................68
Assessment of Causality ..................................................................................70
Medically Attended Visits ...............................................................................71
Assessment of Outcomes .................................................................................71
Reporting, Follow-up, and Assessment of AEs ...............................................72
Appendix 5 Protocol Amendment History .........................................................76
Appendix 6 Signature [CONTACT_7919] ..............................................................100
7
CONFIDENTIAL  217212 (VNS 20 -006) 
Protocol Amendment  3.[ADDRESS_348190] 95% Confidence Interval for the Percentage of Participants with 
Adverse Event Based on the Exposed Set and for the Percentage of 
Participants with Seroresponse Based on the Per Protocol Set........................ 49
Table  11 Analysis Sets ....................................................................................................50
Table  12 Study Administrative Structure........................................................................6 2
Table  13 Intensity Scales for Solicited Symptoms in Toddlers (12 to 15 Months 
of Age) .............................................................................................................69
8
CONFIDENTIAL  217212 (VNS 20 -006) 
Protocol Amendment  3.0 
TABLE OF FIGURES  
Figure  1 Study Design Overview ...................................................................................22
Figure 2 Communication Flow: Identification of Holding Rules by [CONTACT_3786] ......................................................................................................44
9
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 1.0 PROTOCOL SUMMARY  
1.1 Synopsis  
Protocol Title:  A phase II, observer -blind, randomized, controlled study to evaluate the 
immunogenicity and safety of a varicella vaccine at various potencies compared with Varivax , as 
a first dose, administered in healthy children in their second year of life.  
Short Title:  A study on the immune response and safety of various potencies  of an 
investigational chickenpox vaccine compared with a marketed chickenpox vaccine, given to 
healthy children 12 to 15 months of age . 
Rationale : Varicella (chickenpox) is an acute , highly contagious infectious  disease caused by 
[CONTACT_285106]. Safe and effective varicella vaccines have shown to have significant  
global and national  public health impact  when implanted in national immunization plans, e.g. , as 
in the [LOCATION_002] of America (US) . Glaxo SmithKline Biologicals SA ([COMPANY_004]) is developi[INVESTIGATOR_007] a 
candidate varicella vaccine (VNS vaccine). The main purpose of this study is to demonstrate the 
immunogenicity of the investigational VNS vaccine in 3 potencies compared with commercially 
available [COMPANY_006]’s va ricella vaccine, Varivax  (hereafter designated as VV vaccine) , when given 
as a first dose to children 12 to 15 months of age. In this study, all  participants recruited in the 
US will be co -administered with a measles, mumps and rubella  vaccine ( M-M-R II, also called 
M-M-RVaxPro  in countries outside the US, and hereafter designated as MMR) , a hepatitis A 
vaccine ( Havrix ) and a 13 -valent pneumococcal conjugate vaccine ( Prevnar 13 ). Participants 
recruited outside of the US will be co -administered with MMR , Havrix , and in some countries, 
with Prevnar 13 . Outside the US, Prevnar 13  will only be administered in countries where 
pneumococcal conjugate vaccine is recommended at 12 -15 months as per national immunization 
schedule.  At the end of the study or shortly after the study, depending on the 
vaccines’availability, [COMPANY_004] will provide a second dose of Varivax  and/or Havrix  to participants 
enrolled in non -US countries if local health departments do not routinely provide varicella and/or 
hepatitis A vaccine.  Study participants who do not achieve the pre -specified seroresponse 
threshold cr iteria will be re -vaccinated with a dose of Varivax . 
Objectives , Endpoint s, and Estimands:  The study will evaluate the immune response of the 
investigational VNS vaccine (formulated at 3 different potencies) and the VV vaccine in terms of 
geometric mean co ncentration (GMC) and in terms of seroresponse rate  (percentage of 
participants for whom the post -dose anti -glycoprotein E [gE] antibody concentration is 
≥300  mIU/mL)  to gE. The study will also evaluate the safety and the reactogenicity (incidence of 
solicited  adverse events [AEs] , unsolicited  AEs, and serious adverse events [ SAEs]) following 
the administration of the VNS and VV vaccines . 
Overall Design : This will be a  phase II, observer -blind, randomized, multicenter controlled 
study with  5 parallel intervention groups of healthy children aged 12 to 15 months at the time of 
intervention. Participants will be randomized to receive a single dose of an investigational 
varicella vaccine ( 3 groups each receiving one of the 3 different vaccine potencies  [a low, 
medium , and high potency  of the VNS vaccine , respectively ]) or a single dose of a comparator 
licensed varicella vaccine ( 2 groups  each receiv ing one of the 2 different lots  of the VV vaccine , 
which will be pooled for al l analyses). All participants in the US will be co -administered with 
MMR , Havrix , and Prevnar 13  vaccines . Participants recruited outside of the US will be 
co-administered with MMR , Havrix , and in some countries, with Prevnar  13. Outside the US, 
10
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.[ADDRESS_348191] 60 days prior to 
study entry.  
Randomization to one of the 5 groups will be performed in a 2:2:2:1:1 ratio prior to intervention . 
There will be 3 study visits, at Day 1 (intervention) , Day 15  (virtual or in-person ), and Day 43, as 
well as [ADDRESS_348192] , at Day 2-3 and Day 181, respectively . 
Number of Participants : Approximately 800 participants  will be randomly assigned to the 
5 study groups to provide approximately 200 enrolled participants per each VNS group  and 
100 enrolled participants per each VV group . Approximately 90% of the enrolled participants are 
expected to be included in the Per Protocol Set (PPS) and evaluated for immunogenicity . 
Intervention Groups  and Duration : 
VNS_Low : VNS  low potency  vaccine, MMR *, Havrix , and Prevnar 13 ** 
VNS_Med : VNS  medium potency  vaccine, MMR *, Havrix , and Prevnar 13 ** 
VNS_High : VNS  high potency  vaccine, MMR *, Havrix , and Prevnar 13 ** 
VV_Lot1 : VV vaccine Lot 1, MMR *, Havrix , and Prevnar 13 ** 
VV_Lot2 : VV vaccine Lot 2, MMR *, Havrix , and Prevnar 13 ** 
*M-M-R II or M-M-RVaxPro , depending on the country . 
**Prevnar  13 will only be administered to participants enrolled in the US and in countries where 
pneumococcal conjugate vaccine is recommended at 12 -15 months as per national immunization 
schedule.  
Statistical Methods:  Three analyses sets will be used in thi s study, the Enrolled Set, the 
Exposed Set (ES), and the PPS. The i ntercurrent medical conditions that may lead to elimination 
from the PPS will be confirmed immunodeficiency conditions, or development of varicella or 
herpes zoster in the interval between study intervention administration and the collection of the 
blood specimen for immunogenicity  at Visit  3. The i mmunogenicity analyses will be based on 
the PPS. The s tatistical analyses in this study will be descript ive. The study includes 
2 immunogenicity objectives  (one primary and one secondary) and one safety objective. The 
GMCs will be summarized by [CONTACT_285107] 95% confidence interval (CI) derived considering 
log-transformed  anti-gE antibody concentrations a re normally distributed with unknown 
variance . The seroresponse rates to gE will be summarized by [CONTACT_285107] 95% C Is. The 
safety analyses will be based on the ES.  
Data Monitoring Committee: An Independent Data Monitoring Committee  comprising of 
clinical experts and a n independent  biostatistician will perform periodic safety reviews of the 
unblinded study data.  
1.2 Schema  
See Figure  1 in Section  4.1.
11
CONFIDENTIAL  217212 (VNS 20 -006) 
Protocol Amendment  3.[ADDRESS_348193]  Visit  1 Safety call Visit  2* Visit  [ADDRESS_348194]  
Time  points Day 1 Day 2-3 Day 15 Day 43 Day 181
Informed consent  ● See Appendix  2 for details  
Check inclusion/exclusion criteria  ● See Section  5.[ADDRESS_348195] demographic data  ● See Section  [IP_ADDRESS]  for details  
Medical history  ● See Section  [IP_ADDRESS]  for details  
Vaccination history  
(protocol -specific vaccines including pneumococcal 
conjugate vaccine  **) ● See Section  [IP_ADDRESS]  for details  
See Section  5.1 for details  
Physical examination  ● See Section  [IP_ADDRESS]  for details  
Randomization  ○ See Section  6.3.2  for details  
Study interventions See Appendix  1 for the definition  
Check contraindications, warnings and precautions 
to study intervention administration  ○ See Section  [IP_ADDRESS]  for details  
Check criteria for temporary delay for enrollment 
and study intervention administration  ● See Section  5.5 for details  
Study group and treatment number allocation  ○ See Section  6.3.3  for details  
Body temperature before study intervention 
administration  ● The preferred location for measuring 
temperature will be the axilla. Fever is 
defined as body temperature 
≥ 38.0°C/100.4°F  
Study intervention (VNS vaccine/VV vaccine,  
MMR , Havrix , and Prevnar 13 **) administration  ● Study participants who do not achieve 
the pre -specified seroresponse 
threshold criteria will be re -vaccinated 
with a dose of Varivax  
Recording of administered study treatment number  ●
12
CONFIDENTIAL  217212 (VNS 20 -006) 
Protocol Amendment  3.[ADDRESS_348196]  Visit  1 Safety call Visit  2* Visit  [ADDRESS_348197]  
Time  points Day 1 Day 2-3 Day 15 Day 43 Day 181
Distribute eDiaries/download the app  
○ An eDiary/personal electronic device 
application (app) will be used to 
capture solicited administration site or 
systemic events. The participant’s 
parent(s)/LAR(s) should be trained on 
the use of the eDiary/app. See 
Appendix  4 for details  
Second dose of Varivax and/or Havri x 
x At the end of the study or shortly after 
the study, depending on the vaccines’ 
availability, [COMPANY_004] will provide a 
second dose of Havrix  and/or Varivax  
in countries where they are not 
routinely provided. The administration 
of the second dose of Havrix  and 
Varivax  is not part of the study 
procedures, however, the 
administration of the second dose (or 
the date of the planned visit for 
administration) should be recorded in 
the eCRF.  
Laboratory assessment
Blood sampling for antibody determination ( ~3 mL) ● See Section  8.1.[ADDRESS_348198] any concomitant medications/vaccinations  ● ● ● ● See Section  6.[ADDRESS_348199] any intercurrent medical conditions  ● See Section  9.[ADDRESS_348200] for safety follow -up ● ● Or any other convenient procedure  
Recording of solicited administration site events 
from Day 1-[ADDRESS_348201] study intervention administration  ○ ○ Only events following the 
administered dose of VNS vaccine or 
VV vaccine will be solicited  
Safety follow -up with clinical staff to review 
post-vaccination safety data  ● 
Recording of solicited systemic events (drowsiness, 
loss of appetite and irritability ) from  Day [ADDRESS_348202] 
study intervention administration  ○ ○ ○ See Section  8.3 and Appendix  4 
13
CONFIDENTIAL  217212 (VNS 20 -006) 
Protocol Amendment  3.[ADDRESS_348203]  Visit  1 Safety call Visit  2* Visit  [ADDRESS_348204]  
Time  points Day 1 Day 2-3 Day 15 Day 43 Day 181
Recording of solicited systemic events  (fever , 
varicella -like rash  [including  injection site 
varicella -like rash ] and general rash [not varicella -
like]) from  Day 1-[ADDRESS_348205] study intervention 
administration  ○ ○ ○ ○ See Section  8.[ADDRESS_348206] 
study intervention administration  ● ● ● ● See Section  8.3 and Appendix  4 
eDiary /app completion reminder  ● 
Review of eDiaries/app data  ○ ● ● 
Return of eDiaries/uninstall or disable the app  ○ See Section  8.5 for details  
Recording of SAEs  ● ● ● ● ● See Section  8.3 for details and 
Appendix  4 for the definition  
Recording of SAEs related to study participation, or 
to a concurrent [COMPANY_004] medication/vaccine  ● ● ● ● ● The collection and reporting period s 
start once the participant’s 
parent(s)/LAR(s)’s informed consent 
is obtained  
Study conclusion  ● See Section  4.3 for the definition.  
AE = adverse event; App = application; eDiary = Electronic Diary; gE =  glycoprotein E ; LAR = legally acceptable representative ; MMR = M-M-R II or M-M-
RVaxPro ; SAE = serious adverse event;  
VNS vaccine = investigational vaccine; VV vaccine = comparator vaccine  (Varivax ); MMR , Havrix , and Prevnar 13 = co-administered vaccines . 
Note s: 
*Visit  2 (Day 15) may be conducted in -person or virtually.
** Prevnar 13  will only be administered to participants  in the [LOCATION_002] and in the countries where pneumococcal conjugate vaccine is recommended at 12 -15
months as per national immunization schedule . 
● is used to indicate a study procedure that requires documentation in the individual electronic case report form (eCRF).
○ is used to indicate a study procedure that does not require documentation in the individual eCRF.
x  is used to indicate a procedure (that is not part of the study) that requires documentation in the individual eCRF
Refer to  Table  4 for allowed intervals between study vis its. 
Refer to the Study Reference Manual  /pharmacy manual  for the volume of the vaccine after reconstitution.  
14
CONFIDENTIAL  217212 (VNS 20 -006) 
Protocol Amendment  3.0 
 Table  4 Intervals Between Study Visits 
Interval  Planned visit interval * Allowed interval range  
Visit  1→ Safety call 1 to 2 days 1 to 3 days 
Visit  1→Visit  2 14 days 14 to 19 days 
Visit  1→Visit  3 42 days  35 to 56 days  
Visit  1→ Safety follow -up contact  180 days  180 to 201 days  
*Number of days between the visits.
Note: Whenever possible , the investigator should arrange study visits following the planned visit interval. Deviation from allowed interval between Visit  1 and
Visit  3 will lead to elimination from the Per Protocol Set.
15
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 2.0 INTRODUCTION  
2.1 Study Rationale  
Varicella (i.e., chickenpox) is an acute, highly contagious infectious disease caused by [CONTACT_285108] , which typi[INVESTIGATOR_285092] [ADDRESS_348207]  when implanted in national immunization plans, e.g. , as in the [LOCATION_002] of 
America (US) and many other countries worldwide.  
GlaxoSmithKline Biologicals SA ( hereafter designated as [COMPANY_004]) is developi[INVESTIGATOR_007] a candidate 
varicella vaccine (VNS vaccine ). Th e main purpose of this study is to demonstrate the 
immunogenicity of the investigational VNS vaccine in 3 potencies  (designated as VNS_Low 
vaccine, VNS_Med vaccine , and VNS_High vaccine) , when compared with the commercially 
available [COMPANY_006]’s varicella vaccine, Varivax  (designated as VV vaccine) , when given as a first 
dose to children 12 to 15 months of age . In order to obtain more representative data on the 
comparator, participants enrolled in t he VV group will be randomized to 2 different lots 
(designated as VV_Lot1 and VV_Lot2). Throughout the study, the VV lots will be analyzed as 
pooled lot s. 
In addition to assessing the immunogenicity of both varicella vaccines, this study intends to also 
generate safety data in the participants.  
All participants recruited in the US will be co -administered with a measles , mumps , rubella 
vaccine ( M-M-R II, hereafter designated as MMR ), a hepatitis A vaccine ( Havrix ) and a 
13-valent pneumococcal conjugate vacci ne  (Prevnar 13 ). Participants recruited outside of the 
US will be co -administered with an MMR vaccine ( M-M-R II or M-M-RVaxPro  depending on 
the country) , Havrix , and in some countries, with Prevnar 13 . Outside the US,  Prevnar 13  will 
only be administered in countries where pneumococcal conjugate vaccine is recommended at 
12-15 months as per national immunization schedule.  
At the end of the study or shortly after the study, depending on the vaccines’ availability, [COMPANY_004] 
will provide  a second dose of Varivax  and/or Havrix  to participants enrolled in non -US countries 
if local health departments do not routinely provide varicella and/or hepatitis A vaccine.  
Study participants who do not achieve the pre -specified seroresponse threshold c riteria will be 
re-vaccinated with a dose of Varivax . 
2.2 Background  
Varicella is characterized by [CONTACT_59572] a generalized, itchy, vesicular rash. It is commonly 
regarded as a mild childhood illness. However, serious complications such as secondary bacterial 
16
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 infection and pneumonia from varicella infections can occur, leading to hospi[INVESTIGATOR_285093] [ CDC, 2015 ]. 
Universal mass vaccination against varicella is implemented in several countries [ WHO, 2014 ; 
CDC, 2015 ]. It has led to a decrease in varicella morbidity (cases and hospi[INVESTIGATOR_602]) and 
mortality (deaths) [ Wagenpfeil, 2004 ; Siedler, 2010 ; CDC, 2018 ]. 
[COMPANY_004]’s candidate VNS vaccine strain has been derived from an Oka varicella strain. Of the 
varicella strains investigated in preclinical studies, only the Oka strain was considered suitable 
for vaccine production by [CONTACT_38375] (WHO). The vaccines containing this 
strain were developed and evaluated in healthy and immunocompromised adults, adolescents and 
children by [CONTACT_285109]. The VNS vaccine is intended for active 
immunizat ion for the prevention of  varicella in healthy individuals of [ADDRESS_348208] widely used 
varicella vaccines containing an Oka  varicella strain ([COMPANY_006]’s Varivax and [COMPANY_004]’s Varilrix  
vaccines). The summaries of the currently available clinical data on these vaccines are provided 
in the current Investigator ’s Brochure (IB).  
2.3 Benefit/Risk Assessment  
2.3.[ADDRESS_348209]  a benefit -risk profile similar to [COMPANY_006]’s 
Varivax  and [COMPANY_004]’s Varilrix  vaccines. Detailed information about the expected risks and 
reasonably expected adverse events (AEs) of these [ADDRESS_348210] common currently known AEs following administration of varicella vaccine s are local 
reactions, such as pain, soreness, erythema, and swelli ng. Based on the information from the 
manufacturer s’ clinical trials of varicella vaccine s, local reactions are reported by 19% of 
children. These local adverse reactions are generally mild and self -limited. A varicella -like rash 
at the injection site is reported by 3% of children. A median of [ADDRESS_348211] been present. 
These lesions generally occur within 2 weeks  and may be maculopapular rather than vesicular. A 
generalized varicella -like rash is reported by 4% to 6% o f recipi[INVESTIGATOR_285094], 
with an average of [ADDRESS_348212] of these generalized rashes occur within 3 weeks and may be 
mainly maculopapular. Systemic reactions are not common. Fever within 42 days of vaccination 
is reported by 15% of childre n. The majority of these epi[INVESTIGATOR_285095]. Varicella vaccine is a live virus vaccine and may 
17
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 result in a latent infection, similar to that caused by [CONTACT_285110]. Consequently, zoster 
caused by [CONTACT_285111] [CDC, 2015 ] but rarely so . 
Additional risks may be associated with the co -administered vaccines , MMR , Havrix , and 
Prevnar 13 . These vaccines are widely used in the US and some other countries per routine 
pediatric immunization schedule and may cause expected and reasonable AEs. Refer to the 
package insert s or prescribing information for information regarding the summary of adverse 
reactions  of MMR , Havrix , and Prevnar 13 . 
During  this study of the candidate VNS vaccine, there may also be risks related to the blood 
sampling (e.g., bruising and pain at the blood draw site).  
2.3.2 Risk Mitigation Strategies  
For the safety of the participants, the protocol has incorporated various risk miti gation measures , 
including appropriate inclusion and exclusion criteria  (see Section  5.1 and Section  5.2), checking 
contraindications to vaccinations (see Section  [IP_ADDRESS] ) and close monitoring of participants after 
vaccinations . 
All study activities at the study center will be performed by [CONTACT_285112]. The attendance of the s tudy participants  to in-person study visits is 
expe cted to pose  risks that do not extend the risks associated  with clinic visits for routine 
immunization  of children [ADDRESS_348213] should be performed. If the investigator /designee  is not 
successful after the third attempt, the investigator /designee  will make no further attempts. A 
local numbing cream or patch will also be offered at the discretion of the investigator prior to 
blood sampling, to minimize pain when blood samples are drawn . 
The blinded monitoring of study data will be performed  by [CONTACT_285113]’s designee/Contract 
Research Organization (IQVIA) (see study administrative structure in Appendix  2 [Table  12]). 
Additional unblinded safety monitoring will be performed by [CONTACT_269395] (IDMC) . Monthly  Safety Review Team (SRT) review by [CONTACT_285114] 200 participants, to monitor cumulative, 
blinded safety data (including serious and non -serious AEs) (see Section  8.2.3 ). In addition , for 
the first 200 study participants through their Day 43 follow -up, the following criteria would be 
applied, that would result in a pause in study activities, including dosing and enrollment : 
a. Any death  considered at least possibly related to vaccination  (refer to Section  8.3.3 for 
expedited reporting)  
18
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 b. ≥1 participant with SAE (s) considered at least possibly related to vaccination (refer to 
Section  8.3.3  for expedited reporting)  
c. ≥2 participants with the same or similar Grade 3 unsolicited adverse events (AE)  
considered to be at least possibly related to vaccination , (refer to Section  8.3.[ADDRESS_348214]/visit)  
Note: “similarity ” of the events  will be based on medical judgment.  
An enrollment pause is also foreseen for the first IDMC review after 200 participants 
(approximately 50 participants in each group, considering pooled VV groups) are enrolled and 
vaccinated. The analysis will take place once all [ADDRESS_348215] returned for their Day 43 
visit ( Visit  3) or have withdrawn from the study, within the allowed interva l for the visit. A 
positive outcome of the IDMC review will be a pre -requisite for the continuation of the study.  
[COMPANY_004]/IQVIA  will immediately notify the investigator s if any additional safety or toxicology 
information becomes available during the study.  
This study will be performed in compliance with the protocol, I nternational Council for 
Harmonisation (ICH)  Good Clinical Practice (GCP) , European Union (EU)  CTR, and a pplicable 
regulatory requirements. Aspects of the study concerned with the investigational medicinal 
products  will meet the requirements of E U – Good Manufacturing Practice , as applicable.  
2.3.[ADDRESS_348216] varicella.  
By [CONTACT_285115]-administered vaccines MMR , Havrix , and Prevnar  13 [if applicable]  
vaccines ), the participants are expected to be protected against measles, mumps and rubella 
(MMR ), hepatitis A ( Havrix ) and pneumococcal infections ( Prevnar 13 , if applicable ). 
All participants will undergo a physical examination at the first study visit; these evaluations, 
made by [CONTACT_285116], may potentially provide participants’ parent(s)/ legally 
acceptable representatives ( LAR [s]; see  the definition in Appendix  1) with valuable knowledge 
about the participant’s health.  In case the study staff disc overs any medical condition, the 
participant may be referred to the local healthcare system.  
2.3.4 Overall Benefit/Risk Conclusion  
Taking into account the measures taken to minimize possible  risks to  the participants in this 
study, the potential risks associated with  the study intervention (s) and study assessments are 
balanced by [CONTACT_285117].  
19
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 3.0 OBJECTIVES AND ENDPOINTS  
Table  5 Study O bjectives and Endpoints  
Objectives  Endpoints  
Primary  
• To evaluate the immune response of VNS vaccine 
(formulated with different potencies) and VV 
vaccine in terms of geometric mean concentration 
at Day 43 • Anti-gE antibody concentration at Day 43 
Secondary  
• To evaluate the immune response of VNS vaccine 
(formulated with different potencies) and VV 
vaccine in terms of seroresponse rate * at Day 43 • Seroresponse to gE at Day 43 
• To evaluate safety and reactogenicity following 
administration of VNS and VV vaccines  Solicited events  
• Percentage of participants reporting each solicited 
administration site event in terms of injection site 
redness, pain and swelling within 4 days ( Day 1 to 
Day 4) post -dose of VNS vaccine or VV vaccine  
• Percentage of participants reporting each solicited 
systemic event in terms of fever , varicella -like 
rash†, and general rash  (not varicella -like) within 
43 days ( Day 1 to Day 43) post -dose of study 
interventions ** 
• Percentage of participants reporting each solicited 
systemic event in terms of drowsiness, loss of 
appetite , and irritability  within 15 days (Day  1 to 
Day 15) post -dose of study interventions ** 
Unsolicited adverse events (AEs) *** 
• Percentage of participants reporting unsolicited AEs 
within 43 days ( Day 1 to Day 43) post -dose of 
study interventions ** 
Serious adverse events (SAEs)  
• Percentage of participants reporting SAEs 
post-dose of study interventions ** up to the end of 
study  
AE = adverse event; gE = glycoprotein E; SAE = serious adverse event; VNS vaccine = investigational vaccine , VV 
vaccine = comparator vaccine ( Varivax ). 
*Seroresponse rate is defined as the percentage of participants for whom post -dose of the study  interventions 
(Day 43), the anti-gE antibody concentration is ≥300  mIU/mL.  
**Study interventions = VNS vaccine (investigational vaccine); VV vaccine ( Varivax , comparator vaccine); MMR 
(M-M-R II or M-M-RVaxPro ), Havrix  and Prevnar 13  (if applicable) vaccines  (co-administered vaccines).  
Note:  Prevnar  13 will only be administered to participants enrolled in the [LOCATION_002] and in countries where 
pneumococcal conjugate vaccine is recommended at 12 -15 months as per national immunization schedule  
*** Unsolicited AEs include non -serious and serious AEs . 
† Includes injection site varicella -like rash . 
20
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 4.0 STUDY DESIGN  
4.1 Overall  Design  
This will be a phase II, observer -blind (see the definition in  Appendix  1), randomized, 
multicenter controlled study with 5 parallel intervention groups o f healthy children aged 12 to 
15 months at the time of intervention. Participants will be randomized to receive a single dose of 
an investigational varicella vaccine (3 groups of 200 participants each receiving one of the 3 
different vaccine potencies [a  low, a medium, and a  high potency of the VNS vaccine, 
respectively]) or a single dose of a comparator licensed varicella vaccine (2 groups of 
100 participants each receiving one of the 2 different lots of the VV vaccine , which will be 
pooled f or all analyses).  
All participants will be co -administered with a n MMR vaccine , a hepatitis A vaccine ( Havri x) 
and, if applicable,  a 13-valent pneumococcal conjugate vaccine ( Prevnar 13 ). Prevnar 13  will 
only be administered to participants enrolled in th e US and in countries where pneumococcal 
conjugate vaccine is recommended at 12 -15 months as per national immunization schedule .  
At the end of the study or shortly after the study, depending on the vaccines’ availability, [COMPANY_004] 
will provide a second dose of Varivax  and/or Havrix  to participants enrolled in non -US countries 
if local health departments do not routinely provide varicella  and/or hepatitis A vaccine. Study 
participants who do not achieve the pre -specified seroresponse threshold criteria will be 
re-vaccinated with a dose of Varivax .  
The study design diagram is provided in Figure  1. 
21
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Figure  1 Study Design Overview  
 
VNS_Low, VNS_Med, and VNS_High vaccine = VNS vaccine in low, medium, and high potency; VV_Lot 1 and 
VV_Lot 2 = VV vaccine in [ADDRESS_348217] (by [CONTACT_285118]) for the safety follow -up will take place [ADDRESS_348218]-dose of study interventions  
c Study interventions: VNS vaccine (investiga tional vaccine) or VV vaccine ( Varivax , comparator vaccine); MMR 
(M-M-R II or M-M-RVaxPro ), Havrix , and Prevnar 13  if applicable  (co-administered vaccines) . Note: Prevnar [ADDRESS_348219] -vaccination safety data may be a virtual visit  
h Safety call to remind completion of the e lectronic Diary/ smartphone application  and address any potential early 
post-vaccination safety concerns  
*Drowsiness, loss of appetite, irritability  
**Fever, varicella -like rash (including injection site varicella -like rash) and general rash (not varicella -like) 
Healthy children age d 12 to 15 m onths will be enrolled in this study according to the inclusion 
and exclusion criteria (see Section  5.0). The r andomization to one of the 5 groups will be 
performed in a 2:2:2:1:1 ratio prior to intervention.  
The study groups are shown in Table  6. 
22
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Table  6 Study Groups  
Study 
groups  Number of 
participants  Age 
(Min -Max)  Study interventions  Blinding  
Visit  1 → Safety follow -up 
contact  (observer -blind)  
VNS_Low  200 12 – 15 months  VNS_Low vaccine, MMR , 
Havrix , and Prevnar 13 * × 
VNS_Med  200 12 – 15 months  VNS_Med vaccine, MMR , 
Havrix , and Prevnar 13 * × 
VNS_High  200 12 – 15 months  VNS_High vaccine, MMR , 
Havrix , and Prevnar 13 * × 
VV_Lot 1  100 12 – 15 months  VV vaccine ( Varivax Lot 1) , 
MMR , Havrix , and 
Prevnar  13* × 
VV_Lot 2  100 12 – 15 months  VV vaccine ( Varivax Lot 2) , 
MMR , Havrix , and 
Prevnar  13* × 
VNS_Low, VNS_Med, and VNS_High vaccine = VNS vaccine in low, medium, and high potency ; VV_Lot 1 and 
VV_Lot 2  vaccines  = VV vaccine in 2 lots; MMR = M-M-R II or M-M-RVaxPro ; MMR, Havrix , and Prevnar 13  = 
co-administered vaccines  
*Prevnar 13  will only be administered to participants  enrolled in the [LOCATION_002] and in the countries where 
pneumococcal conjugate vaccine is recommended at 12 to 15 months as per national immunization schedule  
There will be 3 in-person study visits: on Day 1, when the participants receive study 
intervent ion, on Day 15 (either in -person or virtually , for review of post -vaccination safety data ), 
and on Day 43, when blood sampling for vaccine antibody testing will be performed. There will 
also be [ADDRESS_348220] , on Day 181; these  may be 
performed over the phone or by [CONTACT_285119].  Refer to the 
Study Reference Manual  which will contain a guide telephone script to be used for the Day  2-3 
safety call, Day  15 (if the visit is conducted virt ually) and for the Day  181 safety follow -up call . 
The visits should occur within a pre -defined visit window (see  Table  4). 
The study will be performed in the observer -blind manner (see the definition in Appendix  1 and 
additional details in Section  4.2.3 ). An IDMC  will perform periodic safety reviews of the study 
data. An enrol lment pause is foreseen for the first IDMC review after 200 participants 
(approximately 50 participants in each group, considering pooled VV groups) are enrolled and 
vaccin ated (See Section  8.2.3  for additional details) . 
The s afety data will be collected th rough an Electronic Diary ( eDiary )/personal electronic device  
application (app)  for solicited events and at study visits/contacts for unsolicited events. The 
humoral immunogenicity testing of blood samples will be performed by [CONTACT_28745] -linked 
immunosorbent assay ( ELISA ) method at [COMPANY_004]’s laboratory or in a laboratory designated by 
[CONTACT_23983].  
23
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 4.2 Scientific Rationale for Study Design  
4.2.1 Rationale for C linical Study Population  
Varicella (chickenpox) is common in children under [ADDRESS_348221] dose a t 12 to 
18 months of age [ WHO , 2014 ]. In the US, the incidence of varicella has decreased significantly 
since implementation of the national varicella vaccination program in 1996 [ CDC, 2015 ]. In the 
US, as per the recommendation of the Advisory Committee on Immunization Practices (ACIP) 
children are routinely administered the first dose of the varicella vaccine at [ADDRESS_348222] 3 months  
[ACIP, 2007 ]. 
4.2.[ADDRESS_348223] of care.  
[IP_ADDRESS]  Comparator  
The varicella vaccine manufactured by [CONTACT_44873] & Co, Varivax , similarly to the investigational 
VNS vaccine, contains an Oka  varicella strain and is intended for the vaccination against 
varicella in healthy individuals from [ADDRESS_348224] of care.  
[IP_ADDRESS]  Co-administered Vaccines  
MMR , Havrix , and Prevnar 13 vaccines  are part of the routine pediatric vaccination schedules in 
the US  [ACIP, 2007 ] and some other countries . 
4.2.3 Rationale for Blinding  
Because of the difference in the presentation of the investigational VNS vaccine and the 
commercial VV vaccine, i.e., the difference in the labeling of the vaccine vials and the difference 
in the appearance of the diluent presentation ( a prefilled syringe for VNS vaccine versus a vial 
for the VV vaccine) , double blinding is not possible. The study will be conducted in an 
observer -blind manner.  See the definitions of double -blinding and observer -blind in Appendi x 1 
and refer to Section  6.3.4  for details.  
24
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 4.2.4 Justification for Dose of Varicella Vaccine  
In general, v aricella dosing recommendations include 1 or 2 doses. In the US, it is recommended 
that the pediatric population receives 2 doses of varicella vaccine . In EU, vaccination with 
2 doses of varicella vaccine is recommended in different countries according to local and 
regional public health guidelines.  
The p articipants in this study will receive a single dose  of investigational or comparator  varicella 
vaccine. The second dose of varicella vaccine will not be offered in this study , as the study 
participants wil l not yet reach an appropriate age  within the study time frame  as per the ACIP 
recommend ed schedule [ACIP,  2007 ]. 
4.[ADDRESS_348225] completed the study if he/she return s for the last visit /contact  
[CONTACT_285120]/contact [INVESTIGATOR_21094].  
The end of the study (EoS) is defined as the date of the Last Partic ipant  Last Visit  (LPLV) or 
date of last testing results released whichever comes last. In the latter, EoS must be achieved no 
later than 8  months after the L PLV. 
25
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 5.0 STUDY POPULATION  
Participants shall be enrolled into the study according to inclusion criteria  and if they meet none 
of the exclusion criteria. Prospective approval of protocol deviations to enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.  
5.1 Inclusion Criteria  
• Healthy participants  as established by [CONTACT_43045].  
• A male or female between, and including, 12 and 15 months of age (i.e. , from his/her 1-year 
birthday until the day before age of 16 months) at the time of the administration of the study 
intervention s. 
• Written informed consent obtained from the parent(s)/LAR(s) of the participant prior to 
performance of any study -specific procedure.  
• Participants’ parent(s)/LAR(s), who, in the opi[INVESTIGATOR_871], can and will comply, 
with the requirements of t he protocol (e.g., completion of eDiaries, return for follow -up 
visits).  
• Only for US  participants  and participants in  countries where pneumococcal conjugate 
vaccine is recommended at 12 -15 months of life as per national immunization schedule : 
Participants who previously received the primary series of pneumococcal conjugate vaccine 
in their first year of life with the last dose at least 60 days prior to study entry.  
5.2 Exclusion Criteria  
5.2.1 Medical Conditions  
• History of any reaction or hypersensitivity likely to be exacerbated by [CONTACT_285121].  
• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on 
medical history and physical examination (no laboratory testing required).  
• Hypersensitivity to latex.  
• Major congenital defects, as assessed by [CONTACT_093].  
• History of vari cella.  
• Recurrent history of or uncontrolled neurological disorders or seizures.  
• Participant with history of SARS -CoV -2 infection who is still symptomatic . 
• Any other clinical condition that, in the opi[INVESTIGATOR_871], might pose additional risk 
to the participant due to participation in the study.  
 
26
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Refer to Section  5.5 for criteria for temporary delay or enrollment and/or intervention.  
5.2.2 Prior  and C oncomitant Therapy  
• Use of any investigational or non -registered product (drug, vaccine or medical device) other 
than the study interventions during the period beginning 30 days before the dose of study 
interventions ( Day -29 to Day 1), or planned use  during the study period.  
• Chronic administration (defined as more than 14 days in total) of immunosuppressants, or 
other immune -modifying drugs during the period starting 90 days prior to the study 
interventions administration. For corticosteroids, this wi ll mean prednisone equivalent 
≥ 0.5 mg/kg/day or 20 mg/day whichever is the maximum dose for pediatric participants, or 
equivalent. Inhaled and topi[INVESTIGATOR_14271].  
• Administration of immunoglobulins and/or any blood products or plasma derivatives during 
the period starting 180 days before the dose of study interventions or planned administration 
during the study period.  
• Administration of long -acting immune -modifying drugs at any time during the study period 
(e.g., infliximab).  
• Previous vaccination against measles, mumps, rubella, hepatitis A , and/or varicella virus.  
• Previous administration of a booster dose of any pneumococcal conjugate vaccine.  
• Planned administration/administration of a vaccine not foreseen by [CONTACT_285122] 30 days before the dose and ending at 43 days after the dose of study 
interventions administration * (Visit  3) with the exception of inactivated influenza ( flu) 
vaccine which may be given at any time during the study and administered at a different 
location than the study interventions.  
Any other age-appropriate vaccine may be given starting at Visit  3 and anytime thereafter.  
*In case of emergency mass vaccination for an unforeseen public health threat (e.g. , a 
pandemic) is recommended and/or organized b y public health authorities outside the routine 
immunization program, the time period described above can be reduced if necessary  for that 
vaccine , provided it is used according to the local governmental recommendations and that 
the Sponsor /designee  is not ified accordingly . 
5.2.3 Prior/ Concurrent Clinical Study Experience  
• Concurrently participating in another clinical study, at any time during the study period, in 
which the participant has been or will be exposed to an investigational or a 
non-investigational int ervention (drug/invasive medical device  [see the definition in 
Appendix  1]). 
27
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 5.2.4 Other Exclusions  
• Child in care  (see the definition in Appendix  1). 
• Any study personnel’s immediate dependents , family, or household members.  
• Participants with the following high -risk indivi duals in their household:  
o Immunocompromised individuals . 
o Pregnant women without documented history of varicella . 
o Newborn infa nts of mo thers without documented history of varicella . 
o Newborn infants born < 28 weeks of gestation.  
5.3 Lifesty le Consideration s, Activity, and Dietary Restrictions  
No restrictions for this study . 
5.4 Screen Failures  
Not applicable as there is no screening phase of the potential participants as part of this study.  
5.5 Criteria for Temporary Delay for Enrollment and/or Intervention 
Administration  
Enrollment  and/or study intervention administration may be postponed  within the permitted time 
interval until transient circums tances cited below are resolved  and the participant stay s eligible : 
• Acute disease and/or fever at the time of enrollment and/or study intervention administration. 
Fever is defined as temperature ≥  38.0°C (100.4°F) by [CONTACT_28414].  The preferred location for 
measuring temperature will be the axilla.  
• Participants with a minor illness (such as mild diarrhea, mild upper respi[INVESTIGATOR_4416] ) 
without fever may be enrolled and/or dosed at the discretion of the investigator . 
• Use of antipyretics and/or analgesics and /or antibiotics within 3  days prior to study 
intervention administration.  
28
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 6.0 STUDY INTERVENTION  
For the definition of study intervention, refer to Appendix  1. 
6.1 Study Intervention s Administered  
The study interventions that will be administered in the study are provided in Table  7. 
 
29
CONFIDENTIAL  217212 (VNS 20 -006) 
Protocol Amendment  3.0 
Table  7 Study Intervention Administered  
Study 
intervention  VNS_Low vaccine  VNS_Med vaccine  VNS_High vaccine  Varivax  
Study 
intervention 
formulation:  Live 
attenuated 
varicella 
virus (OKA 
strain)  
(≥ 1×103.0
pfu/dose ) Water for 
injections  Live attenuated 
varicella virus 
(Oka strain)  
(≥ 1×103.0 
pfu/dose ) Water for 
injections  Live attenuated 
varicella virus 
(Oka strain)  
(≥ 1×103.0 
pfu/dose ) Water for 
injections  Varicella virus 
Oka/[COMPANY_006] 
strain (live, 
attenuated) 
(≥ 1350 
pfu/dose)  Water for 
injections q.s. 
0.5 mL  
Presentation:  Powder for 
suspension 
for injection 
(vial) Solution for 
suspension 
for injection 
(syringe)  Powder for 
suspension for 
injection ( vial) Solution for 
suspension 
for injection 
(syringe)  Powder for 
suspension for 
injection ( vial) Solution for 
suspension for 
injection 
(syringe)  Powder for 
suspension for 
injection ( vial) Solution for 
suspension for 
injection  
Type:  Biologic/Combination 
Product  Biologic/Combination Product  Biologic/Combination Product  Biologic/Combination Product  
Route of 
administration:  Subcutaneous injection  Subcutaneous injection  Subcutaneous injection  Subcutaneous injection  
Administration site:  
Location  Arm Arm Arm Arm 
Directionality  Upper  Upper  Upper  Upper  
Laterality  Left Left Left Left 
Number of 
doses to be 
administered:  1 1 1 2***  
Volume to be 
administered *: At least 0. [ADDRESS_348226] 0.5 mL  0.5 mL  
Packaging  and 
labeling  Refer to S RM for more details  Refer to S RM for more details  Refer to S RM for more details  Refer to S RM for more details  
Manufacturer:  [COMPANY_004]  [COMPANY_004]  [COMPANY_004]  [COMPANY_006] & Co.  
30
CONFIDENTIAL  217212 (VNS 20 -006) 
Protocol Amendment  3.0 
 Study intervention  
(co-administered)  MMR  Havrix  Prevnar  13** 
Study intervention 
formulation:  Live attenuated 
measles virus 
Enders' 
Edmonston strain 
(≥ 3.0 log 10 
TCID 50); Live 
attenuated mumps 
virus Jeryl Lynn™ 
[Level B] strain 
(≥ 4.1 log 10 
TCID 50); Live 
attenuated rubella 
virus Wistar RA 
27/3 strain (≥  3.0 
log 10 TCID 50) Water 
for 
injection
s q.s. 0.5 
mL Hepatitis A virus antigen 
(HM175 strain) (720 ELISA 
Units) adsorbed on aluminum 
hydroxide; Aluminum 
hydroxide (0.25 mg Al3+); 
Water for injections q.s. 0.5  mL PS1(2.2 µg) -CRM 197 adsorbed on aluminum phosphate; 
PS3(2.2  µg)-CRM 197 adsorbed on aluminum phosphate; 
PS4(2.2  µg)-CRM 197 adsorbed on aluminum phosphate; 
PS5(2.2  µg)-CRM 197 adsorbed on aluminum phosphate; 
PS6A(2.2  µg)-CRM 197 adsorbed on aluminum phosphate; 
PS6B(4.4  µg)-CRM 197 adsorbed on aluminum phosphate; 
PS7F(2.2  µg)-CRM 197 adsorbed on aluminum phosphate; 
PS9V(2.2  µg)-CRM 197 adsorbed on aluminum phosphate; 
PS14(2.2  µg)-CRM 197 adsorbed on aluminum phosphate; 
PS18C(2.2  µg)-CRM 197 adsorbed on aluminum phosphate; 
PS19A(2.2 µg) -CRM 197 adsorbed on aluminum phosphate; 
PS19F(2.2  µg)-CRM197 adsorbed on aluminum phosphate; 
PS23F(2.2  µg)-CRM 197 adsorbed on aluminum phosphate; 
Aluminum phosphate (0.125 mg Al3+); 
Water for injections q.s. 0.5  mL 
Presentation:  Powder for 
suspension for 
injection ( vial) Solution 
for 
suspensi
on for 
injection  Suspension for injection 
(syringe ) Suspension for injection ( syringe ) 
Type:  Biologic/Combination Product  Biologic/Combination Product  Biologic/Combination Product  
Route of 
administration:  Subcutaneous injection  Intramuscular injection  Intramuscular injection  
Administration site:  
Location  Arm Thigh  Thigh  
Directionality  Upper  Anterolateral  Anterolateral  
Laterality  Right  Right  Left 
Number of doses to be 
administered:  1 2*** 1 
Volume to be 
administered*: 0.5 mL  0.5 mL  0.5 mL  
Packaging  and labeling Refer to SRM for more details  Refer to SRM for more details  Refer to SRM for more details  
Manufacturer:  [COMPANY_006] & Co  [COMPANY_004]  [COMPANY_007]  
TCID 50 = tissue cell culture infectious dose s 50%; PS = polysaccharide; CRM 197 = non -toxic cross -reacting  mutant of diphtheria toxin;  ELISA = e nzyme -linked immunosorbent 
assay; [COMPANY_004] = GlaxoSmithKline Biologicals SA; pfu = plaque-forming units; SRM = Study Reference Manual;  VNS_ Low, VNS_Med, and VNS_ High  = VNS vaccine in  low, 
medium, and high potency ; MMR  = measles, mumps, rubella vaccine ( M-M-R II or M-M-RVaxPro ) 
*Refer to the S tudy Reference Manual /pharmacy manual  for the volume after reconstitutio n
31
CONFIDENTIAL  217212 (VNS 20 -006) 
Protocol Amendment  3.0 
 **Prevnar 13  will only be administered to participants  enrolled in the [LOCATION_002] and in countries where pneumococcal conjugate vaccine is recommended at 12 to 15 months as 
per national immunization schedule  
*** For non -US participants only. A t the end of the study or shortly after the study,  depending on the vaccines’ availability, [COMPANY_004] will provide a second dose of 
Havrix  and/or Varivax  in countries where they are not routinely provided.  The administration of the second dose of Havrix  and Varivax  is not part of the study 
procedures.
32
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 6.2 Preparati on/Handling/Storage /Accountability  
The study intervention(s) must be stored at the respective label storage temperature conditions in 
a safe and locked place. Access to the storage space should be limited to authorized study 
personnel. The storage conditio ns will be assessed during pre -study activities under the 
responsibility of the sponsor study contact. The storage temperature should be continuously 
monitored with calibrated (if not validated) temperature monitoring device(s) and recorded. 
Refer to the Study Reference Manual (SRM )/pharmacy manual  for more details on storage of the 
study intervention (s). 
Varivax  will be stored at −15°C to −30°C (+5°F to −22°F) in the US and other countries with 
frozen formulation  and at +2°C to +8°C (+36°F to +46°F) in the rest of the world.  (Note: 
refrigerated Varivax  vaccine will be used at non -US sites, while frozen Varivax  vaccine will be 
used at sites in the US  and other countries with frozen formulation .) 
Temperature excursions must be reported in degree Celsius , as described below:  
• For VNS Diluent  
Any temperature excursion outside the range of +1.5°C to +8. 4°C (for +2 to +8°C/+36 to +46°F 
label storage condition) impacting investigational medicinal products (IMPs) must be reported in 
the appropriate (electronic) temperature excursion decision form ([e]TDF). The impacted IMPs 
must not be used and must be stored in quarantine at label temperature conditions until usage 
approval has been obtained from the sponsor. The impacted IMPs may still be administe red, but 
the site should avoid re -occurrence of such temperature excursion. Refer to the SRM/pharmacy 
manual for more details on actions to take.  
• For VNS Antigen  
Any temperature excursion above −15.0°C (for −20°C/ −4°F label storage condition) impacting 
IMPs must be reported in the appropriate  (electronic) Temperature Excursion Decision Form  
(e)TDF. The impacted IMPs must not be used and must be stored in quarantine at label 
temperature conditions until usage approval has been obtained from the sponsor. In c ase of 
temperature excursion above −20.0°C up to −15.0°C impacting IMPs, there is no need to report 
in (e)TDF, but adequate actions must be taken to restore the −20°C/ −4°F or below label storage 
temperature. The impacted IMPs may still be used, but the sit e should avoid re -occurrence of 
such temperature excursion. Refer to the SRM/pharmacy manual for more details on actions to 
take.  
• For Varivax Diluent , Varivax  antigen  with  refrigerated formulation  and all other 
products (Prevnar 13 , Havrix , MMR ) 
Any temperature excursion outside the range of 2.0°C to +8.0°C (for +2 °C to +8°C/+36 °F to 
+46°F label storage condition) impacting study interventions must be reported in the appropriate 
33
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 (e)TDF. The impacted study interventions must not be used and must be sto red in quarantine at 
label temperature conditions until usage approval has been obtained from the sponsor.  
• For Varivax  Antigen  in the US  and other countries  with  frozen formulation  
Any temperature excursion above −15.0°C impacting study interventions must be reported in the 
appropriate (e)TDF . The impacted study interventions must not be used and must be stored in 
quarantine at label temperature conditions until usage approval has been obtained from the 
sponsor.  
All study interventions th at are impacted by a temperature excursion may not be used and must 
be quarantined at label storage conditions until usage approval has been obtained from/via the 
local study contact (e.g. , Site Monitor). Refer to the SRM/pharmacy manual for details and 
instructions on the temperature excursion reporting and usage decision process, packaging , and 
accountability of the study interventions.  
6.2.1 Minimizing Environmental Contamination with Genetically Modified 
Organisms  
Not applicable . 
6.3 Measures to Minimize Bias: Ra ndomization and Blinding  
6.3.1 Participant Identification  
The p articipant identification numbers (IDs) will be assigned sequentially to the participants 
whose parent (s)/LAR (s) have consented to participate in the study, according to the range of 
participant IDs allocated to each study center.  
6.3.2 Randomization to Study Intervention  
The country  and center will be used as minimization factors for randomization. Randomization 
of vacci nes will be performed using Interactive Voice Response System (IVRS)/Interactive Web 
Response System (I WRS ). The participants will receive a unique treatment number (refer to 
Appendix  1 for the definition). Once a treatment number has been assigned, it cannot be 
re-assigned.  
6.3.3 Intervention Allocation to Participants  
Allocation of the participant to an intervention group at the study center will be performed using 
IVRS /IWRS  randomization through Interactive Response Tool (IRT; refe r to Appendix  1 for the 
definition) operated at the study level, before the first vaccination and after assessment of 
eligibility (i.e., after screening conclusion).  The country  and center will be used as minimization 
factors.  
34
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 The actual randomization assignment the participant received (to one of the groups) will be 
identifiable via IRT in case of unblinding.  
After obtaining the signed and dated Informed Consent Form ( ICF) from the participant’s 
parent(s)/LAR(s) and having chec ked the eligibility of the participant, the delegated clinical 
study staff will access IVRS /IWRS . Upon entering the participant ID, the randomization system 
will determine the intervention group and provide the treatment  number.  
Refer to the IVRS /IWRS  user guide or the S RM for specific instructions related to instances 
when IVRS /IWRS  is not available.  
Refer to the S RM for additional information related to the treatment number  allocation.  
6.3.4 Blinding and Unblinding  
Data will be collected in an observer -blind manner. To do so, study interventions will be 
prepared and administered by [CONTACT_285123], evaluation, review , or the entry of any study endpoint.  
The laboratory in charge of sample testing will be blinded to the study intervention assignment. 
Codes will be used to link the participant and study to each sample. There will be no link 
between the study intervention groups and the identity of the participant.  
[IP_ADDRESS]  Emergency Unblinding  
Unblinding a participan t’s individual treatment number should occur ONLY in case of a medical 
emergency when knowledge of the intervention is essential for the clinical management or 
welfare of the participant.  
In case of emergency, the investigator will have unrestricted, immed iate, and direct access to the 
participant’s individual study intervention through IVRS /IWRS . At activation, the study centers 
will be provided instructions and/or other applicable information for emergency unblinding . The 
IRT used by [CONTACT_21926] /IWRS  provide r will be programmed with blind -breaking instructions. In 
case of an emergency, the investigator has the sole responsibility for determining if unblinding of 
a participant’s intervention is warranted. The p articipant safety must always be the first 
conside ration in making such a determination.  
If a participant’s intervention assignment is unblinded, the Medical Monitor (see the definition in 
Appendix  1) must be notified within [ADDRESS_348227] be recorded in the source documentation  (see the definition in 
Appendix  1) and electronic Case Report Form ( eCRF ), as applicable. The participant may 
continue in the study.  
In the event of a Quality Assurance audit, the auditor(s) may be allowed access to unblinded 
study treatment information records to verify that vaccine dispensing has been done accurately.  
35
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 A physician other than the investigator (e.g., an emergency room physician) or partic ipant’s 
parent(s)/LAR(s)/caregiver (see the definition in Appendix  1)/family member may also request 
emergency unblinding. Instructions for this will be provided to the participants’ parent (s)/LAR (s) 
at enrollment.  
[IP_ADDRESS]  Emergency Un blinding Prior to Regulatory Reporting of Serious Adverse Events  
[COMPANY_004] policy (which incorporates ICH E2A guideline, EU Clinical Study Directive, and US 
Federal Regulations) is to unblind the report of any unexpected SAE that is 
attributable/suspected to be attributable to the investigational vaccine prior to regulatory 
reporting.  
IQVIA  will follow these policies along with IQVIA’s standard procedures and will be 
responsible for unblinding the intervention assignment in accordance with the specified 
timeframe s for expedited reporting of SAEs (refer to Appendix  4 for details ). 
In addition, IQVIA may unblind the intervention assignment for any participant with a suspected 
unexpected serious adverse reaction (S[LOCATION_003]R) or an SAE that is fatal or life -threatening. If the 
SAE requires an expedited regulatory report be sent to 1 or more regulatory agencies, a copy of 
the report, identifying the participant’s intervention assignment, may be sent to investigators in 
accordance with local regul ations and/or the sponsor’s policy.  
6.4 Study Intervention Compliance  
When the study intervention is administered at the study center , participants will receive it from 
the authorized study center staff . The date of administration of each study intervention dose in 
the clinic will be recorded in the source documents and in the eCRF.  
6.5 Dose Modification  
Not applicable.  
6.6 Continuing Access to Study Intervention after the End of the Study  
At the end of the study or shortly after the study, depending on the vaccines’ availability, [COMPANY_004] 
will provide a second dose of Varivax  and/or Havrix  to participants enrolled in non -US countries 
if local health departments do not routinely provide varicella  and/or hepatitis A vaccine.   
6.7 Treatment of Overdose  
Any dose of any study vaccine greater than the recommended dose per protocol is considered an 
overdose. All cases of vaccine overdose should be reported as AEs (or SAEs, if SAE criteria are 
met) and follo wed accordingly. Sponsor does not recommend specific treatment for an overdose.  
36
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 6.8 Concomitant Therapy  
At each study visit/contact, the investigator or designee should question the participant’s 
parent(s)/LAR(s) about any medications/products/supplements take n and vaccinations received 
by [CONTACT_2299], whether prescribed or over the counter.  
The following concomitant therapi[INVESTIGATOR_55340]:  
• All concomitant medication associated with AE, including vaccines/products, except 
vitamins and dietar y supplements, administered after the first dose of study intervention 
(Day 1 to Day 43). 
• All concomitant medication leading to discontinuation of the study intervention or 
elimination from the analysis, including products/vaccines.  
• All concomitant medicat ion which may explain/cause/be used to treat an SAE including 
vaccines/products. These must also be recorded in the Expedited Adverse Event report.  
The Medical Monitor should be contact[CONTACT_63193].  
The record of a concomitant medication should include at a minimum the reason for use, dates of 
administration including start and end dates, dosage information including dose and frequency.  
37
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 7.0 DISCONTINUATION  OF STUDY TREATMENT AND 
PARTICIPANT DISCONTINUATION /WITHDRAWAL  
7.1 Discontinuation of Study Intervention  
Not applicable as this is a single dose study.  
7.2 Contraindications to Subsequent Study Interventions Administration  
Not applicable as this is a single dose study.  
7.3 Participant  Discontinuation/ Withdrawal from the Study  
The participant’s parent(s)/LAR(s) may withdraw the participant from the study at any time or 
the investigator may decide to withdraw a participant for safety, compliance, administrative, or 
other reasons.  
A participant is conside red a “withdrawal” from the study when no study procedure has 
occurred, no follow -up has been performed, and no further information has been collected for 
this participant from the date of withdrawal/last contact.  
From an analysis perspective, a study “wit hdrawal” refers to any participant who was not 
available for the concluding contact [CONTACT_285124].  
All data and samples collected up to and including the date of withdrawal of/last contact [CONTACT_285125](s)/LAR(s)  will be included in  the study analyses.  
The primary reason for study withdrawal shall be documented in the eCRF. Examples of the 
reasons may include:  
• Adverse event requiring expedited reporting to IQVIA  (see Appendix  4 for the details 
regarding s uch events)  
• Unsolicited non -serious AE  
• Solicited AE  
• Withdrawal by [CONTACT_2299] ’s parent(s)/LAR(s)  but not due to AE* 
• Migrated/moved from the study area  
• Lost to follow -up 
• Study termination  
• Other (specify)  
38
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 *If a participant is withdrawn from the study because the participant’s parent(s)/LAR(s) have 
withdrawn consent and the reason for withdrawal was provided, the investigator must document 
this reason in the eCRF.  
Participants who are withdrawn from the study because of SAEs/AEs must be clearly 
distinguished from participants who are withdrawn for other reasons. The investigators should 
follow -up with parent (s)/LAR (s) of participants who are withdrawn from the study as a result of 
an SAE/AE until the event is resolved (see  Appendix  4 for details regarding follow -up for AEs ). 
7.[ADDRESS_348228] to Follow -up 
A participant will be considered “lost to follow -up” if he/she fails to  return for the  scheduled 
visit and cannot be contact[CONTACT_78637] . 
Refer to the S RM for a descriptio n of actions to be taken before considering the participant lost 
to follow -up. 
39
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 8.0 STUDY ASSESSMENTS AND PROCEDURES  
Protocol waivers or exemptions are only permitted when necessary for the management of 
immediate safety concerns for the participant.  
Immediate safety concerns should be discussed with the sponsor as soon as they occur or when 
the study team becomes aware of them. The purpose of this communication is to determine if the 
participant(s) should discontinue the study intervention.  
Study procedures and  their timing are summarized in the Schedule of Activities ( SoA; 
Section  1.3). 
All screening evaluations must be completed and the results reviewed before confirming that 
potential participants meet all eligibility criteria.  
The investigator will maintain a log of all  participants screened. All relevant information, such as 
confirmation of eligibility and reasons for screening failure will be mentioned in this screening 
log. 
The SRM provides the investigator and study center personnel with detailed administrative and 
technical information that does not impact the participant safety.  
8.[ADDRESS_348229] ( IRB) or Independent Ethic s Committee (IEC) 
approval, if required by [CONTACT_19666].  
Information on further research and its rationale can be obtained from [COMPANY_004].  
Sample testing will be done in accordance with the recorded consent of the participant’s 
parent(s)/LAR(s) . 
By [CONTACT_15094], collected samples will be stored for a maximum of [ADDRESS_348230] study visit. This timeline can be adapted based 
on local laws, regulations or guidelines requiring different timeframes or procedures. In all cases, 
the storage period should be aligned with participant’s consent. These additional requirements 
must be formally communicated to, discussed and agreed with [COMPANY_004].  
40
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 8.1.2 Laboratory Assays  
All laboratory testing will be performed as indicated in Table  8 at [COMPANY_004] laboratory or in a 
laboratory designated by [CONTACT_23983].  
Table  8 Laboratory Assay  
Assay type  System  Component  Method  
Humoral Immunity 
(Antibody determination)  Serum  Anti-gE antibodies  ELISA  
gE = glycoprotein E;  ELISA = enzyme -linked immunosorbent assay  
8.1.3 Immunological Correlates of Protection  
There is no established correlate of protection (see the definition in Appendix  1) with the assay 
to be used in this study for the varicella vaccines administered in the frame of this study.  
The investigator, even though remaining blinded with respect to each child’s group attribution, 
will be provided with the list of children who fail to serorespond to varicella virus (i.e. , achieve a 
post-vaccination anti-gE antibody concentration ≥300 mIU/mL) in a timely manner (no later than 
[ADDRESS_348231] child enrolled).  
Upon receiving the result , the investigator will assess if a ny step needs to be taken regarding the 
individual child . Study participants who do not achieve the pre -specified seroresponse threshold 
criteria will be re -vaccinated with a dose of Varivax . 
8.2 Safety Assessments  
8.2.1 Pre-intervention Administration Procedures  
[IP_ADDRESS]  Collection of Demographic Data, Medical/vaccination history, Physical 
Examination  
Demographic data such as age in months, sex, race , and ethnicity will be collected from each 
participant. Medical history should be collected and it should be veri fied that none of exclusion 
criteria related to medical and vaccination history ( Section  5.2) are met. Prior vaccination history 
with respect to pneumococcal conjugate vaccine  should be obtained and recorded in the eCRF.  
Physical examination will be performed for each participant. If the investigator determines that 
the participant’s health on the day of the study intervention administration temporari ly precludes 
dosing, the visit will be rescheduled. Refer to Section  5.[ADDRESS_348232] of criteria for  the temporary 
delay of study intervention administration.  
[IP_ADDRESS]  Checking Contraindications, Warnings, and Precautions to Intervention 
Administration  
The body temperature of each participant will be measured prior to the study intervention 
administration. [COMPANY_004] will p rovide the study center with the temperature measuring device which 
41
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.[ADDRESS_348233] devices validated by [CONTACT_23983]’s Quality Assurance Team to ensure consistency in the 
data across study centers . If the participant has a fever (defined as temperature ≥ 38.0 ° C 
[100.4° F] regardless  of the location of measurement) on the day of the intervention 
administration, or other health conditions that can be considered temporary, Visit  1 can be 
rescheduled  (see Section  5.5) as long as the elig ibility  criteria are still met ( See Section  5.1 and 
Section  5.2). 
8.2.2 Clinical Safety Laboratory Tests  
No clinical safety laboratory te sts are planned per protocol. Clinical safety laboratory tests may 
be performed at the investigator’s discretion if deemed necessary in case of safety concerns.  
8.2.3 Safety Monitoring  and Study Holding Rules 
Besides safety monitoring by [CONTACT_285126]/ Center  Monitors (see the definition in Appendix  1), 
an IDMC comprising of clinical experts and a n independent  biostatistician will provide safety 
oversight during the active vaccinatio n period, through unblinded review of the cumulative 
safety data.  
Up to the completion of enrollment and vaccination of the first 200 participants  through their 
Day 43 follow -up, enrollment will be paused for an ad hoc IDMC review of the cumulative 
safety data if any of the holding rules  are met (See Section [IP_ADDRESS] ). 
An enrollment pause is foreseen for the first IDMC review after 200 participants (50  in each 
group, considering pooled VV groups) are enrolled and vaccinated. The analysis will take place 
once all [ADDRESS_348234] returned for their Day 43 visit ( Visit  3) or have withdrawn from 
the study, within the allowed interval f or the visit. A positive outcome of the IDMC review will 
be a pre -requisite for the continuation of the study.  
Monthly SRT review will occur up to the enrollment and vaccination of the first 200 participants  
through their Day 43 follow -up, to monitor cumul ative, blinded, safety data (including serious 
and non -serious AEs). The blinded safety data review by [CONTACT_285127] [ADDRESS_348235] returned for their Day 43 visit ( Visit  3) or have withdrawn from the study, 
within the allowed interval for the visit.  
42
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 [IP_ADDRESS]  Study Holding Rules  
The safety h olding rules  defined in Table  [ADDRESS_348236] possibly related to study vaccination  ≥ 1 
2 Any SAE (s) considered at least possibly related to vaccination  ≥ 1 
3 Same or similar* Grade [ADDRESS_348237] possibly 
related to vaccination  ≥ 2 
AE = adverse event; IDMC = Independent Data Monitoring Committee; SAE = serious adverse event  
*based on medical judgment  
If the investigator becomes aware of a holding rule being met, he/she must suspend 
administration of the study intervention , pause  enrollment,  and inform IQVIA  immediately  (e.g., 
holding rules 1 -3). Refer to Appendix  [ADDRESS_348238] be followed  (Figure 2).  
43
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Figure 2 Communication Flow: Identification of Holding Rules by [CONTACT_285128] = Clinical Research and Development Lead; GSB = Global Safety Board; IDMC = Independent Data 
Monitoring Committee;  IVRS  = Interactive Voice Response System ; SRT = Safety Review Team  
*Investigators are responsible to inform the Institutional Review Board /Independent Ethics Committee  if a holding 
rule has been met. 
[IP_ADDRESS]  Outcome of Safety Evaluation  
If a safety s ignal is observed during the safety evaluations , or if any of the holding rules is met 
for the first 200 participants, the IDMC Chair (or his/her representative) is responsible for the 
urgent communication to [COMPANY_004], including t he rationale for the decision to put the study 
intervention administration on hold or not.  
If no safety signal is observed in the first [ADDRESS_348239] of the study on all groups or  on selected groups.  
Refer to Section  [IP_ADDRESS]  for a flow chart for escalation of safety signal.  
8.3 Adverse Events  
8.3.1 Time Period and Frequency for Collecting AE and SAEs an d Other Safety 
Information  
The definitions of an AE or SAE are provided in Appendix  4. 
44
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Collection of AEs starts on the day of  the study intervention  (Day 1) up to Day 43 unless the AE 
leads to study discontinuation . Collection of SAEs starts the day of the study intervention 
(Day 1) and up to Day 181 unless the SAE leads to study discontinuation . The f requency for 
collection of AEs and SAEs is shown in the SoA  (Section  1.3). 
Provided that [COMPANY_004] marketed study interventions  registered in the US are combination products 
(see Table  7, and the definition of a combination product in Appendix  1), associated AEs 
meeting pre -specified definitions will be classified as medical device AEs and SAEs, as  well as 
adverse device effects ( ADEs ), serious adverse device effects ( SADEs ), and unanticipated 
serious adverse device effects ([LOCATION_003]DEs) . Definitions of these events are provided in 
Appendix  4. Details on recording, follow -up and reporting of medical device deficiencies are 
provided in Section  8.3.6 . 
8.3.2 Method of Detecting AEs and SAEs  
The m ethods for detecting and recording AEs and SAEs, and the assessment of AE/SAE 
intensity, causality and outcome are provided  in Appendix  4. 
The study  center staff should instruct participants’ parent (s)/LAR (s) on how to report signs and 
symptoms (e.g., crying and pain) in the individual participant. They will be instructed to report 
both specific and non -specific symptoms.  
Care will be taken not to introduce bias when detecting AEs and SAEs. Open -ended and 
non-leading verbal questioning of the participant s’ parent(s)/LAR(s)  is the preferred method to 
inquire about AE  occurrences.  Examples of the open -ended questions include “Did you have any 
significant medical problem since the last study vis it?” The study center  staff should refrain from 
detailed questions, e .g., “Since the last visit, have you experienced any of the following 
(checklist) ?” 
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. All SAEs will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to follow -up. Further information on follow -up 
procedures is provided in  Appen dix 4. 
8.3.[ADDRESS_348240] report it to IQVIA within 24  hours using an electronic 
Expedited AE Repor t in the eCRF . 
The investigator will provide an assessment of causality at the time of the initial report, as 
defined in the  Appendix  4. New or updated information will be recorded on the originally 
completed form with all changes signed and dated by [CONTACT_285129] 
45
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 within 24 hours.  This is essential for meeting [COMPANY_004] legal obligations and ethical responsibilities 
for the participant ’s safety and the safety of a study intervention under clinical investig ation.  
For coronavirus disease 2019 ( COVID -19)-related SAEs, reports should be submitted following 
routine procedures for SAEs.  
Local regulatory requirements and [COMPANY_004]’s policy for the preparation of an investigator safety 
report for suspected S[LOCATION_003]Rs must be  followed. These reports will be forwarded to investigators 
as necessary.  
[COMPANY_004] has a legal responsibility to notify both the local regulatory authority and other regulatory 
agencies about the safety of a study intervention under clinical investigation. [COMPANY_004] and IQVIA 
will comply with country -specific requirements related to safety reporting to the regulatory 
authority, IRB /IEC , and investigators.  
8.3.[ADDRESS_348241]  
The investigator or investigator’s designee must provide the participant’s parent(s)/LAR(s) with 
a “participant card” containing information about the clinical study. The participant’s 
parent(s)/LAR(s) will be instructed to keep the participant card in their possession at all times 
throughout the study. In an emergency, this card serves to inform the responsible attending 
physician/ caregiver/family member/ participant’s parent(s) /LAR(s) that the participant is in a 
clinical study and t hat relevant information may be obtained by [CONTACT_285130]/her backup . 
8.3.[ADDRESS_348242] information of any device deficiencies associated with the study 
interventions that are combination prod ucts ([COMPANY_004] marketed combination products registered in 
the US) . Refer to Appendix  [ADDRESS_348243] and a medical device 
deficiency.  
[IP_ADDRESS]  Detection, Follow -up, and Reporting of Medical Device Deficiencies  
The investigator is responsible for the detection, documentation and prompt reporting of any 
medical device deficiency occurring during the study to IQVIA . Device deficiencies should be 
reported within 24 hours after the investigator determines that the event meets the protocol 
definition of a device deficiency. New or updated information will be recorded on the originally 
completed form with all changes sign ed and dated by [CONTACT_285131] 24 hours.  
46
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Refer to  Appendix  4 for details on recording and reporting of medical device deficiencies.  
The investigator will ensure to follow the participants with rep orted device deficiencies and 
perform any additional investigations to determine the nature and/or causality of the deficiency.  
[IP_ADDRESS]  Regulatory Reporting of Medical Device Deficiency When Used as Combination 
Product  
The investigator will promptly report all dev ice deficiencies occurring with any medical device 
provided for use in the study in order for [COMPANY_004]  to fulfill the legal responsibility to notify 
appropriate regulatory authorities and other entities about certain safety information relating to 
medical devic es being used in clinical studies. Refer to Appendix  4 for details of reporting.  
The investigator, or responsible person according to local requirements (e.g., the head of the 
medical institution), will comply with the applicab le local regulatory requirements relating to the 
reporting of device deficiencies to the IRB /IEC . 
8.4 Pharmacokinetics  and Pharmacodynamics  
Pharmacokinetic and pharmacodynamic parameters are not evaluated in this study.  
8.5 Study Procedures During Special Circumstances  
During special circumstances (e.g., COVID -19 pandemic), the specific guidance from local 
public health and other competent authorities regarding the protection of individuals’ welfare 
must be followed. For the duration of such special circums tances, the following measures may be 
implemented for enrolled participants:  
• Safety follow -up may be made by a phone call or other means of virtual contact.  
• If the eDiary device was provided to the participant ’s parent(s)/LAR(s) , it may be 
returned to the study center by [CONTACT_285132] (refer to the SRM for details).  If the app was provided to the 
participants’ parent(s)/LAR(s) for use on their personal device, the app can be disabled 
remotely.  
• Visits for suspected AEs may take place in a different location* other than the study 
center or at participant’s home. If this is not fe asible, then the medical evaluation of AEs 
may take place remotely with documentation of symptoms by [CONTACT_285133] (e.g.,  phone call or videoconference), if possible.  
• Biological samples may be collected at a different location* other than th e study center 
or at participant’s home. Biological samples should not be collected if they cannot be 
processed in a timely manner or appropriately stored until the intended use.  
47
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 *Note: It is the investigator’s responsibility to identify an alternate locat ion. The investigator  
should ensure that this alternate location meets ICH G CP requirements, such as adequate 
facilities to perform study procedures, appropriate training of the staff, and documented 
delegation of responsibilities in this location. This al ternate location may need to be covered by 
[CONTACT_285134].  
The impact on the PPS for immunogenicity will be determined on a case -by-case basis. Any 
impact of the above -mentioned measures on the study results will be described in the Clinical 
Study Report  (CSR) . 
48
CONFIDENTIAL  217212 (VNS 20 -006) 
Protocol Amendment  3.0 
9.0 STATISTICAL CONSIDERATIONS  
9.1 Statistical Hypotheses  
There are no statistical hypotheses in this study. All analyses are descriptive . 
9.2 Sample Size Determination  
The target enrol lment will be of 800 participants randomly assigned to 5 study groups 
(VNS_Low, VNS_Med, VNS_High, VV_Lot1 , and VV_Lot2 groups) in a 2:2:2:1:1 ratio. 
Table  10 demonstrates the accuracy which can be achieved in terms of percentage of participants 
with AE based on the ES (200 participants  per group considering pooled VV_Lot1 and VV_Lot2 
groups), and i n terms of percentage of participants with seroresponse based on the PPS 
(10%  unevaluable participants out of the 200 enrolled participants is considered leading to about 
180 participants in the PPS per group).  
Table  [ADDRESS_348244] 95% Conf idence Interval for the Percentage of Participants with  
Adverse Event Based on the Exposed Set and for the Percentage of 
Participants with Seroresponse Based on the Per Protocol Set  
Endpoint  n N % Exact 95% CI  
% of participants with an AE  0 200 0.0 [0.00%; 1.83%]  
10 200 5.0 [2.42%; 9.00%]  
20 200 10.0 [6.22%; 15.02%]  
40 200 20.0 [14.69%; 26.22%]  
Seroresponse rate  144 180 80.0 [73.40%; 85.58%]  
153 180 85.0 [78.93%; 89.885%]  
162 180 90.0 [84.66%; 93.96%]  
171 180 95.0 [90.72%; 97.69%]  
AE =  adverse event; CI = confidence interval ; n/N = number of participants with an observation/total number of 
participants  
See the analysis sets definitions in Section  9.3. Refer to Appendix  1 for the definitions of 
eligible, enrolled, and evaluable participants.  
9.3 Populations for Analyses  
For purposes of analysis, the analysis sets are defined  in Table  11. 
49
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Table  11 Analysis Sets  
Analysis set  Description  
Enrolled Set  Participants who received a study intervention or were rand omized. Note that as per GCP 
enrolled participants’ parent (s)/LAR (s) should have completed the informed consent 
process and participants should be eligible before initiating any study procedure.  
Exposed Set (ES)  All participants who received a study inter vention. Analysis per group is based on the 
varicella intervention administered.  
Per Protocol Set 
(PPS)  All eligible participants who received all study interventions as per protocol, were not 
unblinded, had immunogenicity results post -dose, complied with  blood draw intervals 
(refer to  Table  3), without intercurrent medical conditions that may interfere with 
immunogenicity and without prohibited concomitant medication/vaccination  (see the 
footnote ). 
GCP = good clinical practice; LAR = legally acceptable representative  
Note: Intercurrent medical conditions that may lead to elimination from the PPS are defined as confirmed 
immunodeficiency condition, or development of varicella or herpes zoster in the interval between study intervention 
administration and the collection o f the blood specimen for immunogenicity at Visit  3. 
9.4 Statistical Analyses  
9.4.1 Statistical Analysis Plan  
The statistical analysis plan (SAP) will be developed and finalized before the F irst Participant 
First Visit  (FPFV). This section is a summary of the planned  statistical analyses of the primary 
and secondary immunogenicity endpoints.  
Descriptive analyses of safety and demography summaries will be described in the SAP.  
There is no intention to conduct specific analyses investigating the relationship between the  
gender of the participants and the immunogenicity and safety of the study vaccine. The ratio of 
male to female participants recruited into th is study is expected to be in line with the 
demographics of the population aged 12 to 15 months of age . 
9.4.2 Primary Endpoint Analyses  
The primary analysis of immunogenicity endpoints will be based on the PPS.  
The geometric mean concentrations ( GMCs ) will be summ arized by [CONTACT_285107] 95% CI 
derived considering log -transformed anti-gE antibody concentrations are normally distributed 
with unknown variance. The c oncentration below the assay cut -off will be assigned half the 
cut-off for the purpose of GMC computa tion. 
The group GMC ratio with nominal 95% CI will also be provided. This will be obtained using an 
analysis of variance ( ANOVA ) model on log -transformed concentrations.  The model based on 
the data from all groups will include group and country as a fixed effect.  
50
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.[ADDRESS_348245] -dose anti-gE 
antibody concentration ( Day 43) is ≥  300 mIU/mL.  
The seroresponse rates will be summarized by [CONTACT_285107] 95% exact CI  based on 
Clopper -Pearson method [Clopper and Pearson, 1934 ]. 
The 2 -sided 95% CI on group difference in seroresponse rate (pooled VV group m inus each 
VNS group [Low, Med, High]) will be computed based on the method of Miettinen and 
Nurminen [ Miettinen and Nurmine n, 1985 ]. 
9.5 Interim Analysis  
9.5.1 Sequence of Analyses  
Apart from the analyses  to be performed  in support to the IDMC, a statistical analysis  and a 
report  including safety and final immunogenicity data for all participants up to Day 43 time  point 
are planned. Following unblinding for the analysis up to Day 43, accessibility to group  
attribution will be limited so that the study center  blinding is maintained until the 6 -month safety 
follow -up is completed for all participants.  
One integrated CSR  containing all data including the safety follow -up beyond Day 43 will then 
be generated up on study completion. This report will be made available to the investigators.  If 
there is a delay in availability of the immunogenicity data, leading to a window between the 
2 analyses shorter than what is planned at the time of protocol writing, only 1 statistical analysis 
including all immunogenicity and safety data will be performed.  
9.5.2 Statistical Considerations for Interim Analysis  
All analyses are descriptive and therefore no statistical adjustment for interim analyses is 
required.  
51
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 10.0 REFERENCES  
Advisor y Committee on Immunization Practices (ACIP). Prevention of varicella: 
recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for 
Disease Control, Atlanta, GA. MMWR . 2007;56(No. RR -4). 
Centers for Disease Control and Prevention  (CDC). CDC 24/7: Saving Lives, Protecting People. 
Last reviewed: 31 December 2018. https://www.cdc.gov/chickenpox/hcp/index.html. Accessed: 
22 March 2021 . 
Centers for Disease Control and Prevention (CDC) The Pi[INVESTIGATOR_45508]: Course Textbook; 13th 
Edition April 2015, Updated December 2020; Chapter 22 Varicella. 
http://www.cdc.gov/vaccines/pubs/pi[INVESTIGATOR_45509]/varicella.html. Accessed: 2 2 March  2021.  
Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of 
binomial. Biometrika . 1934; 26 :404-413. 
Miettinen O., Nurminen M. Comparative analysis of 2 rates. Statistics in Medicine  1985; 
4(2):[ADDRESS_348246] of the routine varicella vaccination programme on varicella 
epi[INVESTIGATOR_285096]. Euro Surveill. 2010;15(13).  
Wagenpfeil S, Neiss A, Banz K, et al. Empi[INVESTIGATOR_285097]. Clin Microbiol Infect . 2004;10(5):425 -30. 
World Health Organization (WHO). Varicella Vaccines - WHO Position Paper. WHO, Gene va, 
Switzerland. Weekly Epi[INVESTIGATOR_267624] . 2014;25:265 -288. 
52
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 11.0 APPENDICES  
53
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.[ADDRESS_348247] Visit  
GCP  Good Clinical Practice  
gE Glycoprotein E  
GMC  Geometric Mean Concentration  
HRP  Horseradish Peroxidase  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council for Harmonisation  
ID Identification  
IDMC  Independent Data Monitoring Committee  
IEC Independent Ethic s Committee  
IgG Immunoglobulin G  
IMP Investigational medicinal product  
IRB Institutional Review Board  
IRT Interactive Response Tool  
IVRS  Interactive Voice Response System  
IWRS  Interactive Web Response System  
LAR  Legally Acceptable Representative  
LPLV  Last Participant Last Visit  
MMR  Measles, mumps, and rubella vaccine  
PPS Per Protocol Set  
PS Polysaccharide  
SADE  Serious Adverse Device Effect  
54
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SARS -CoV -2 Severe Acute Respi[INVESTIGATOR_102525] 2  
SoA Schedule of Activities  
SRM  Study Reference Manual  
SRT Safety Review Team  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
(e)TDF  (electronic) Temperature Excursion Decision Form  
US [LOCATION_002] of America  
[LOCATION_003]DE  Unanticipated Serious Adverse Device Effect  
VNS  Varicella vaccine ( investigational vaccine ) 
VV Varicella vaccine (comparator  vaccine ) 
WHO  World Health Organization  
Glossary of Terms  
Adverse event:  Any untoward medical occurrence in a patient or clinical 
investigation participant, temporally associated with the use of a 
medicinal product, whether or not considered related to the 
medicinal product.  
An adverse event can therefore be any unfavorable and unintended 
sign (including an abnormal laborato ry finding), symptom, or 
disease (new or exacerbated) temporally associated with the use of a 
medicinal product. For marketed medicinal products, this also 
includes failure to produce expected benefits (i.e. , lack of efficacy), 
abuse or misuse.  
Blinding:  A procedure in which [ADDRESS_348248] of the study, and only when the d ata are 
cleaned to an acceptable level of quality will appropriate personnel 
be unblinded or when required in case of a serious adverse event. In 
an observer -blind study, the participant ’s parent(s)/LAR(s) , the 
study center and sponsor personnel involved i n the clinical 
evaluation of the participants are blinded while other study 
personnel may be aware of the treatment assignment.  
In a double -blind study, the participant ’s parent(s)/LAR(s) , the 
investigator and sponsor staff who are involved in the treatmen t or 
clinical evaluation of the participants and the review or analysis of 
data are all unaware of the intervention assignment.  
55
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Caregiver:  A caregiver is someone who  
• lives in the close surroundings of a participant and has a 
continuous caring role or  
• has substantial periods of contact [CONTACT_4490] a participant and is 
engaged in his/her daily health care (e.g., a relative of the 
participant).  
Certified copy:  A copy (irrespective of the type of media used) of the original record 
that has been verified (i.e. , by a dated signature [INVESTIGATOR_4388] [CONTACT_163568] a validated process) to have the same information, including 
data that describe the context, content, and structure, as the original.  
Child in care:  A child who has been placed under the control or protection of an  
agency, organization , institution or entity by [CONTACT_285135], the 
government or a government body, acting in accordance with 
powers conferred on them by [CONTACT_6617]. The definition of a 
child in care can include a child cared for by [CONTACT_285136] l iving 
in a care home or institution, provided that the arrangement falls 
within the definition above. The definition of a child in care does not 
include a child who is adopted or has an appointed legal 
guardian/LAR(s).  
Combination 
product:  Combination pro duct comprises any combination of  
• drug 
• device  
• biological product  
Each drug, device, and biological product included in a combination 
product is a constituent part.  
Eligible:  Qualified for enrollment into the study based upon strict adherence 
to inclusion/exclusion criteria.  
Enrollment:  The process of registering a participant into a clinical study by 
[CONTACT_285137].  
Enrolled participant:  “Enrolled” means a participant’s parent’s/LAR’s agreement  to 
participate in a clinical study following completion of the informed 
consent process. Potential participants who are screened for 
determining eligibility for the study, but do not participate in the 
study, are not considered enrolled.  
Essential docume nts: Documents which individually and collectively permit evaluation of 
the conduct of a study and the quality of the data produced.  
56
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Evaluable:  Meeting all eligibility criteria, complying with the procedures 
defined in the protocol, and, therefore, includ ed in the per  protocol 
analysis.  
Immunological 
correlate of 
protection:  A correlate of risk that has been validated to predict a certain level 
of protection from the targeted endpoint.  
Intervention:  Term used throughout the clinical study to denote a set of 
investigational product(s) or marketed product(s) or placebo 
intended to be administered to a participant.  
Invasive medical 
device:  A device which, in whole or in part, penetrates inside the body, 
either through a body orifice or through the surfac e of the body  
Investigational 
vaccine/product:  A pharmaceutical form of an active ingredient being tested in a 
clinical study, including a product with a marketing authorization 
when used in a way different from the approved form, or when used 
for an unap proved indication, or when used to gain further 
information about an approved use.  
Investigator:  A person responsible for the conduct of the clinical study at a study 
center. If a study is conducted by a team of individuals at a study 
center, the investig ator is the responsible leader of the team and may 
be called the principal investigator.  
The investigator can delegate study -related duties and functions 
conducted at the study center to qualified individual or party to 
perform those study -related duties a nd functions.  
Interactive 
Voice /Web 
Response System : The software that enables the randomizing of participants into 
clinical trials and allocation of the study product to them in a blinded 
fashion. This technology allows study centers to interact with a 
database by [CONTACT_285138] a phone and foll owing voice 
or online prompts in order to enter in information.  
Legally acceptable 
representative:  An individual or juridical or other body authorized under applicable 
law to consent, on behalf of a prospective participant, to the 
participant's participat ion in the clinical trial. The terms legal 
representative and legally authorized representative are used in some 
settings.  
Medical device 
deficiency:  A device deficiency is an inadequacy of a medical device with 
respect to its identity, quality, durabilit y, reliability, safety, or 
performance. Device deficiencies include malfunctions, use errors 
and information supplied by [CONTACT_3455].  
57
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Medical Monitor
  IQVIA’s delegate providing significant scientific contribution to the 
conduct of the study. The ter ms Medical Officer, Medical Advisor 
are also used in some settings.  
Medically attended 
AEs:  Symptoms or illnesses requiring hospi[INVESTIGATOR_059], or emergency room 
visit, or visit to/by a health care provider.  
Participant:  An individual who se parent(s)/LAR(s)  has been contact[CONTACT_285139], either as a recipi[INVESTIGATOR_285098](s)/product or as a control.  
Participant ID: A unique identification number assigned to each participant who 
consents to participate in the study.  
Protocol 
amendment:  The ICH defines a protocol amendment as “A written description of 
a change(s) to or formal clarification of a protocol.” [COMPANY_004] further 
details this to include a change to an approved protocol that affects 
the sa fety of participants, scope of the investigation, study design, or 
scientific integrity of the study.  
Randomization:  Process of random attribution of intervention to participants to 
reduce selection bias.  
Safety Review 
Team:  This team lead by [CONTACT_285140], clinical, epi[INVESTIGATOR_623], regulatory, and statistics 
departments, who are also part of the study team. For this study, the 
team is responsible for reviewing observed safety concerns based on 
blinded safet y data.  
Solicited events:  Events to be recorded as endpoints in the clinical study. The 
presence/occurrence/intensity of these events is actively solicited 
from the participant or an observer during a specified follow -up 
period following study interventio n administration.  
Source data:  All information in original records and certified copi[INVESTIGATOR_1930], observations, or other activities in a 
clinical study necessary for the reconstruction and evaluation of the 
study. Source da ta are contained in source documents (original 
records or certified copi[INVESTIGATOR_014]).  
Source documents:  Original legible documents, data, and records (e.g., hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, participants' 
diaries or evaluation checklists, pharmacy dispensing records, 
recorded data from automated instruments, copi[INVESTIGATOR_164372], microfiches, 
photographic negatives, microfilm or magnetic media, x -rays, 
58
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 particip ant files, and records kept at the pharmacy, at the laboratories 
and at medico -technical departments involved in the clinical study).  
Study/Center 
Monitor:  An individual assigned by [CONTACT_23983]/IQVIA (see the study administrative 
structure in Appendix  2 [Table  12]) and responsible for assuring 
proper conduct of clinical studies at 1 or more study centers. The 
terms Clinical Research Monitor and Clinical Research Associate 
are used in some settings.  
Study intervention:  Any investigational or marketed product(s) or placebo intended to be 
administered to a participant during the study.  
Treatment number:  A number identifying intervention given to a participant, according 
to intervention allocation.  
Unsol icited events:  Any AE reported in addition to those solicited during the clinical 
study. Also, any “solicited” symptom with onset outside of the 
specified period of follow -up for solicited symptoms will be 
reported as an unsolicited AE.  
59
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Appendix  2 Regulatory, Ethical, and Study Oversight Considerations  
Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with:  
− Consensus ethical principles derived from international guidelines including the 
Declaratio n of Helsinki and Council for International Organizations of Medical 
Sciences International Ethical Guidelines  
− Applicable ICH GCP Guidelines  
− Applicable laws and regulations  
• The protocol, protocol amendments  (see the definition in Appendix  1), ICF, IB, and 
other relevant documents (e.g.,  advertisements) must be submitted to an IRB /IEC  by [CONTACT_285141]. These documents will be signed and dated by [CONTACT_285142].  
• Any protocol amendments will require IRB /IEC  approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an 
immediate hazard to study participants. Furthermore,  any substantial amendments to t he 
protocol may require regulatory authority approval before implementation per local 
legislation.  
• IQVIA will provide full details of the above procedures to the investigator, either 
verbally, in writing, or both.  
• The investigator will be responsible for t he following:  
− Providing written summaries of the status of the study to the IRB /IEC  annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201] /IEC . 
− Notifying the IRB /IEC  of SAE(s) or other significant s afety findings as required by 
[CONTACT_1744]/IEC  procedures.  
− Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 Code of Federal Regulations ( CFR ), ICH guidelines, the IRB /IEC , 
European regulation 536/2014 for clinical stud ies (if applicable) , and all other 
applicable local regulations.  
• After reading the protocol, all principal  investigator s will sign the protocol signature 
[CONTACT_41452] a copy of the signed page to IQVIA ( Appendix  6). 
Financial Disclosure  
Investigators and sub -investigators will provide IQVIA  with sufficient, accurate financial 
information as requested to allow [COMPANY_004] /IQVIA  to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing financial interest information prior initiation of the study center and at 
60
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 the end of t he study. Investigators are responsible for providing a financial disclosure update if 
their financial interests change at any point during their participation in a study and for 1 year 
after completion of the study.  
Informed Consent Process  
• The investigat or or his/her representative must fully explain the nature of the study to the 
participant’s parent(s)/LAR(s) and answer all questions regarding the study.  
• Participants’ parent(s)/LAR(s) must be informed that their participation is voluntary.  
• Freely given and written/witnessed/thumb printed informed consent must be obtained 
from each participant’s parent(s)/LAR(s)/witness, as appropriate, prior to participation in 
the study.  
• The content of the ICF must meet the requirements of [ADDRESS_348249] requirements, where 
applicable, and the IRB /IEC  or study center.  
• The medical record must include a statement that written or witnessed/thumb printed 
informed consent was obtained before th e participant was enrolled in the study and the 
date the consent was obtained. The authorized person obtaining the informed consent 
must also sign the ICF.  
• Participants ’ parent(s)/LAR(s)  must be re -consented to the most current version of the 
ICF(s) or an ICF addendum during their participation in the study.  
• A copy of the ICF(s) must be provided to the participants’ parent(s)/LAR(s).  
Data Protection  
• Any participant records or datasets that are transferred to IQVIA /[COMPANY_004] will contain the 
participant ID only; p articipant names or any information which would make the 
participant identifiable will not be transferred.  
• The participants’ parents/LARs must be informed that : 
− Their child’s study -related data will be used by [CONTACT_285143] l aw. 
− Their child’s medical records may be examined by [CONTACT_285144]/IQVIA, by [CONTACT_99473]/IEC  members, and by [CONTACT_6668].  
− [COMPANY_004] will ensure protection of the personal data of the investigator and study center 
staff which is collected within the framework of and for the purpose of the study, in 
accordance with the Data Pri vacy Notice that will be sent to the site staff.  
The participants’ parent(s)/LAR(s) must be notified about their rights regarding the use of their 
personal data in accordance with the data privacy section of the ICF.  
61
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.[ADDRESS_348250], and/or [COMPANY_004] Clinical Study Register in compliance with applicable 
regulations/[COMPANY_004] policy. [COMPANY_004] will aim to register protocols summaries prior to stu dy start and 
target results summaries submission within 12 months of primary/study completion date. Where 
external regulations require earlier disclosure, [COMPANY_004] will follow those timelines.  
Where required by [CONTACT_5151], summaries will also be posted on appli cable national or regional 
clinical study registers.  
Where required by [CONTACT_25435], an investigator signatory will be 
identified for the approval of the study report, and provided reasonable access to statistical 
tables, figures, and  relevant reports. [COMPANY_004] will also provide the investigator with the full 
summary of the study results. The investigator is encouraged to share the summary results with 
the study participants ’ parent(s)/LAR(s) , as appropriate.  
[COMPANY_004] will provide the investigat or with the randomization codes for their site only after 
completion of the full statistical analysis.  
[COMPANY_004] intends to make anonymized patient -level data from this study available to external 
researchers for scientific analyses or to conduct further researc h that can help advance medical 
science or improve patient care. This helps  to ensure the data provided by [CONTACT_175063].  
Publication Policy  
[COMPANY_004] aims to submit for publication t he results of the study in searchable, peer reviewed 
scientific literature within 18 months from LPLV and follow authorship and other guidance from 
the International Committee of Medical Journal Editors.  
62
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Data Quality Assurance  
• The investigator should maint ain a record of the location(s) of their respective essential 
documents, including source documents (see  Appendix  1 for definition s of essential and 
source documents). The document storage system used during the study and for archiving 
(irrespective of the type of media used) should provide for document identification, version 
history, search, and retrieval.  
• Essential study documents may be added or removed where justified (in advance of study 
initiation) based on their importance and relevance to the study. When a copy is used to 
replace an original document (e.g. , source documents, eCRF), the copy should fulfill the 
requirements for certified copi[INVESTIGATOR_014] (see  Appendix  1 for the definition of a certified copy ). 
• All participant data related to the study will be recorded on printed or eCRF unless transmitted 
to [COMPANY_004]/IQVIA electronically (e.g. , laboratory data). The  investigator is responsible for 
verifying that data entries are accurate and correct by [CONTACT_21496].  
• The investigator must maintain adequate and accurate source documents and study records that 
include all pertinent obser vations on each of the site’s study participants (see  Appendix  1 for 
the definition of source documents) that supports information entered in the eCRF.  
• The investigator must permit study -related monitoring, audits, IRB /IEC  review, and regulatory 
agency inspections and provide direct access to source documents or certified copi[INVESTIGATOR_285099].  
• IQVIA is responsible for the data management of this study including quality checking of the 
source data (see  Appendix  1 for the definition of source data).  
• Study monitors will perform ongoing source data verification to confirm that data entered in 
the eCRF by [CONTACT_122710], legible, contemporaneous, original, 
accur ate, and complete. Changes to source data must be traceable, not obscure the original 
entry, and be fully explained if necessary (e.g. , via an audit trail). The safety and rights of 
participants must be protected, and the study conducted in accordance with  the currently 
approved protocol and any other study agreements, ICH GCP, and all applicable regulatory 
requirements.  
• Quality tolerance limits will be pre -defined to identify systematic issues that can impact 
participant safety and/or the reliability of st udy results.  
• Study records and source documents pertaining to the conduct of this study, including signed 
ICFs, must be retained by [CONTACT_1732] 25 years from issuance of the final 
CSR/equivalent summary unless local /country -specific regulations or institutional policies 
require a longer retention period. No records may be destroyed during the retention period 
63
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 without the written approval of [COMPANY_004]. No records may be transferred to another location or 
party without writt en notification to [COMPANY_004].  
Source Documents  
• Source documents provide evidence to establish the existence of the participant and 
substantiate the integrity of collected data. The investigator should maintain a record of the 
location(s) of their source document s. 
• Data transcribed into the eCRF from source documents must be consistent with those source 
documents; any discrepancies must be explained. The investigator may need to request 
previous medical records or transfer records, depending on the study. Also, cu rrent medical 
records must be available.  
• Definitions of what constitutes source data and documents can be found in Appendix  1. 
Study and Study Center Start and Closure  
The first act of recruitment is the date of the first parti cipant enrollment and is considered the 
study start date.  
[COMPANY_004]/IQVIA reserves the right to close the study center or terminate the study at any time for any 
reason. Study center s will be closed upon study completion. A study center  is considered closed 
when  all required documents and study supplies have been collected and a study center closure 
visit has been performed.  
The investigator may initiate study center  closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance  of the intended termination.  
Reasons for the early closure of a study center may include but are not limited to:  
• Failure of the investigator to comply with the protocol, the requirements of the IRB /IEC  or 
local health authorities, [COMPANY_004]’s procedures, or GCP  guidelines  
• Inadequate recruitment of participants by [CONTACT_093]  
• Discontinuation of further study intervention development  
• Total number of participants included earlier than expected  
If the study is prematurely terminated or suspended, [COMPANY_004]/IQVIA shal l promptly inform the 
investigators, the IRBs /IECs , and the regulatory authorities of the reason for termination or 
suspension, as specified by [CONTACT_1214]. The investigator shall 
promptly inform the participants and should assur e appropriate participant therapy and/or 
follow -up. 
64
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Appendix  3 Clinical Laboratory Tests  
Enzyme -linked immunosorbent assay  
Anti-gE ELISA is a two -step ELISA based on the antibody and antigen interaction, which allows 
the detection and the quantification of specific immunoglobulin G ( IgG) antibodies directed 
against gE in tested serum samples.  
Briefly, diluted serum samples are  added onto a [ADDRESS_348251] human IgG antibodies and conjugated to horseradish 
peroxidase (a -IgG-HRP) are added and will bind to anti -gE IgG if present. After a washing step, 
the ad dition of a chromogen -substrate solution specific for HRP will provide means of detecting 
the anti -gE specific for the pre -coated antigen. The HRP catalyzes an enzymatic reaction which 
is stopped by [CONTACT_285145], resulting in a color chan ge from blue to yellow.  
The optical density recorded is proportional to the concentration of the anti -gE antibodies present 
in the serum sample. Antibod y titre is expressed in mIU/ mL. 
65
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Appendix  4 Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  
Adverse Events  
AE Definition  
• An AE is any untoward medical occurrence in a patient or clinical study participant that is temporally 
associated with the use of study intervention, whether or not considered related to the study intervention.  
An AE can, therefore, be any unfavorable and unintended sign, symptom, or disease (new or exacerbated) 
temporally associated with the use of study intervention.  
 
Events Meeting  the AE Definition  
• Significant or unexpected worsening or exacerbation of the condition/indication under study.  
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase in frequency 
and/or intensity of the condition.  
• New conditions detected or diagnosed after stud y intervention administration even though they may have 
been present prior to the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose  of either study in tervention.  
• Signs or symptoms temporally associated with study intervention administration.  
• Signs, symptoms that require medical attention (e.g., hospi[INVESTIGATOR_7959], physician visits, and emergency 
department visits).  
• Pre- or post -intervention events that occu r as a result of protocol -mandated procedures (i.e., invasive 
procedures).  
• Clinically significant abnormal laboratory findings following the start of the study.  
 
Events NOT  Meeting the AE Definition  
• Situations where an untoward medical occurrence did not occur (e.g., social and/or convenience admission to 
a hospi[INVESTIGATOR_307], admission for routine examination).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or detected at the start 
of the study that do not worsen.  
• Pre-existing conditions or signs and/or symptoms present in a participant prior to the first/the study 
vaccination. These events will be recorded in the medical history section of the eCRF.  
• Hospi[INVESTIGATOR_5187] a pre -existing c ondition (known or diagnosed prior to informed 
consent signature) that did not worsen from baseline.  
• Clinically significant abnormal laboratory findings or other abnormal assessments, unless judged by [CONTACT_285146] p articipant’s condition, or that are present or detected at the 
start of the study and do not worsen.  
• However, if 1 or both of the following conditions apply, then the event should be reported promptly to 
IQVIA as an SAE:  
− The event is, in the investigator’s  opi[INVESTIGATOR_1649], of greater intensity, frequency, or duration than expected for 
the individual participant, or  
− The investigator considers that there is a reasonable possibility that the event was related to the 
administration of the study intervention.  
66
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Serious Adverse Events  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (e.g., hospi[INVESTIGATOR_1080]/symptoms of the disease under study).  
An SAE is defined as any untoward medical occurrence th at, at any dose:  
a) Results in death  
b) Is life -threatening  
The term “life -threatening” in the definition of “serious” refers to an event in which the participant was at risk of 
death at the time of the event. It does not refer to an event that hypothetically might have caused death had it been 
more severe.  
c) Requires inpatient hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_285100]/or treatment that would not have been appropriate in the physician’s office or in an out -patient 
setting. Complications that occur during hospi[INVESTIGATOR_285101]. If a complication prolongs 
hospi[INVESTIGATOR_23919], the event will also be considered serious. When in doubt as to 
whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the AE should be considered serious.  
d) Results in disability/incapacity  
The term disability means a substantial disruption of a person’s ability to conduct normal life functions. This 
definition is not intended to include experiences of relatively minor medical significance such as uncomplicated 
headache, nausea, vomiting, diarrhea, influenza -like illnes s, and accidental trauma (e.g., sprained ankle) which 
may interfere or prevent everyday  life functions but do not constitute a substantial disruption.  
e) Other situations  
• Medical or scientific judgment should be exercised in deciding whether reporting is app ropriate in other 
situations, such as important medical events that may not be immediately life -threatening or result in death or 
hospi[INVESTIGATOR_285102]. These should also be considered serious. Examples 
of such events are invasive or malignant cancers, intensive treatment in an emergency department or at home 
for allergic bronchospasm, blood dyscrasias, or convulsi ons that do not result in hospi[INVESTIGATOR_059].  
Solicited Events  
Solicited Events will include the following:  
a) Solicited administration site events  
The following administration site events will be solicited for toddlers 12 to 15 months of age  at the time of the 
study intervention : 
• Pain 
• Redness  
• Swelling  
b) Solicited systemic events  
The following systemic events will be solicited for toddlers  12 to 15 mon ths of age  at the time of the study 
intervention : 
67
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Solicited Events will include the following:  
• Fever  
• Varicella -like rash  (including injection site varicella -like rash ) 
• General rash (not varicella -like) 
• Drowsiness  
• Loss of appetite  
• Irritability  
Note: participants’ parent(s)/LAR(s) will be instructed to measure and record body temperature in the evening  
using  the temperature measuring device provided by [CONTACT_23983] . The recommended route of temperature measurement 
will be the axilla. Should additional temperature measurements be performed at other t imes of day, participants’ 
parent(s)/LAR(s) will be instructed to record the highest temperature in the eDiary /personal electronic devic e 
app. 
Unsolicited Events  
Definition of an Unsolicited Adverse Event:  
An unsolicited AE is an AE that was not included  in a list of solicited events using a n eDiary /personal electronic  
device  app. Unsolicited events must have been spontaneously communicated by a participant’s parent(s)/LAR(s) 
who have signed the informed consent. Unsolicited AEs include both serious and non -serious AEs.  
Potential unsolicited AEs may be medically attended (i.e., sym ptoms or illnesses requiring a hospi[INVESTIGATOR_059] , or an 
emergency room visit, or visit to/by a health care provider). The participant’s parent(s)/LAR(s) will be instructed 
to contact [CONTACT_285147](s), as well  as any events that, though not 
medically attended, are of participant/parental/LAR (s)’ concern. Detailed information about reported unsolicited 
AEs will be collected by [CONTACT_285148]’s records.  
Unsolici ted AEs that are not medically attended or perceived as a concern by [CONTACT_2299]’s parent(s)/LAR(s) 
will be collected during an interview with the participant’s parent(s)/LAR(s) and by [CONTACT_285149].  
COVID -19 Cases  
Diagnosis of COVID -19 should be made in accordance with the WHO case definition. Cases 
should be categorized as AEs (unsolicited or AEs leading to withdrawal) or SAEs, and routine 
procedures for recording, evaluation, follow -up, and reportin g of AEs and SAEs should be 
followed in accordance with the time period set out in the protocol.  
Assessment of Intensity and Toxicity  
The intensity of the following solicited AEs will be assessed as described in Table  13. 
68
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Table  13 Intensity Scales for Solicited Symptoms in Toddlers (12 to 15 Months of Age)  
Toddler (12 to 15 months of age)  
Adverse Event  Intensity Grade  Parameter  
Pain at injection site  0 None  
1 Mild: Minor reaction to touch  
2 Moderate: Cries/protests on touch  
3 Severe: Cries when limb is moved/spontaneously painful  
Redness at injection site  Greatest surface diameter in mm  
Swelling at injection site  Greatest surface diameter in mm  
Fever* Temperature in °C/°F  
Varicella -like rash** Number of lesions  
General rash (not 
varicella -like)  0 None  
1 Mild: R ash which is easily tolerated by [CONTACT_2252], causing minimal 
discomfort and not interfering with everyday activities  
2 Moderate: Rash which is sufficiently discomforting to interfere with 
normal everyday activities  
3 Severe: Rash which prevents normal, everyday activities (in a young 
child, such an AE would, for example, prevent attendance at 
school/day care and would cause the parent(s)/LAR(s) to seek 
medical advice)  
Drowsiness  
 0 Behavior as usual  
1 Mild: Drowsiness easily tolerated  
2 Moderate: Drowsiness that interferes with normal activity  
3 Severe: Drowsiness that prevents normal activity  
Loss of appetite  
 0 Appetite as usual  
1 Mild: Eating less than usual/no effect on normal activity  
2 Moderate: Eating less than usual/interferes with normal activity  
3 Severe: Not eating at all  
Irritability  
 0 Behavior as usual  
1 Mild: Crying more than usual/no effect on normal activity  
2 Moderate: Crying more than usual/interferes with normal activity  
3 Severe: Crying that cannot be comforted/prevents normal activity  
*Fever is defined as temperature ≥ 38.0°C (100.4°F) by [CONTACT_28414].  The preferred location for measuring temperature 
will be the axilla.  
**A typi[INVESTIGATOR_285103] -like rash manifests as a rash/lesions that  may appear within 2 weeks  (or sometimes later) after 
the varicella vaccination . Lesions may contain  spots, bumps, blisters, or crusts.  Refer to the Study Reference Manual  
for detailed varicella -like r ash guidelines . 
The maximum intensity of administration site redness/swelling/fever/varicella -like rash will be 
scored as follows:  
 Redness/swelling  Varicella -like rash* Fever† 
0 None  None  < 38.0°C (100.4°F)  
1 > 0 - ≤ 5 mm  1-25 lesions  ≥ 38.0°C (100.4°F) - ≤ 39.0°C (102.2°F)  
2 > 5 - ≤ 20 mm  26-50 lesions  > 39.0°C (102.2°F) - ≤ 39.5°C (103.1°F)  
3 > 20 mm  ≥ 51 lesions  > 39.5°C (103.1°F)  
*Including injection site varicella -like rash  
†Temperature will be analyzed in 0.5°C increments from ≥ 38 .0°C (≥ 100.4°F).  
69
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 The investigator will assess the maximum intensity that occurred over the duration of the event 
for all unsolicited AEs (including SAEs) recorded during the study. The assessment will be 
based on the investigator’s clinical judgment.  
The intensity should be assigned to 1 of the following categories:  
1 (mild)  = An AE that is easily tolerated by [CONTACT_126727], causing minimal 
discomfort and not interfering with everyday  activities.  
2 (moderate)  = An AE that is sufficiently discomforting to interfere with normal 
everyday  activities.  
3 (severe)  = An AE that prevents normal everyday  activities. Such an AE 
would, for example, prevent attendance at a childcare facility and 
would cause the parent(s)/LAR(s) to seek medical advice.  
An AE that is assessed as Grade 3 (severe) should not be confused with an SAE. 
Grade  3 is a categor y used for rating the intensity of an event; and both AEs and SAEs 
can be assessed as Grade 3. An event is defined as “serious” when it meets one of the 
pre-defined  outcomes as described above.  
Assessment of Causality  
All solicited administration site and systemic events will be considered causally related to 
administration of the study intervention. The complete list of these events is provided in 
Table  13. 
Alternative possible causes, such as the natural history of underlying disease, concomitant 
therapy, other risk factors, and the temporal relationship of the event to the study intervention 
will be considered and in vestigated. The investigator will also consult the IB and/or the 
Summary of Product Characteristics and/or Prescribing Information for marketed products to 
assist in making his/her assessment.  Causality should be assessed by [CONTACT_159290]:  
Is there a reasonable possibility that the unsolicited AE may have been caused by [CONTACT_285150]?  
YES  : There is a reasonable possibility that the study intervention 
contributed to the AE.  
NO : There is no reasonable possibility that the AE is causally related to 
the administration of the study intervention. There are other, more 
likely causes and administration of the study intervention is not 
suspected to have contributed to the AE.  
70
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 If an event meets the criteria to  be determined as “serious”, additional examinations/tests will be 
performed by [CONTACT_285151].  
Possible contributing factors include:  
• Medical history.  
• Other medication.  
• Protocol required proced ure. 
• Other procedure not required by [CONTACT_760].  
• Lack of efficacy of the study intervention, if applicable.  
• An error in study intervention administration.  
Other cause (specify). There may be situations when an SAE has occurred, and the investigator 
has m inimal information to include in the initial report to IQVIA. However, it is very important 
to record an assessment of causality for every event before submitting the Expedited AE Report 
to IQVIA.  
The causality assessment is one of the criteria used when d etermining regulatory reporting 
requirements. The investigator may change his/her opi[INVESTIGATOR_163518].  
Medically Attended Visits  
For each solicited and unsolicited AE the pa rticipant experiences, the participant’s 
parent(s)/LAR(s) will be asked if the participant received medical attention (defined as 
hospi[INVESTIGATOR_059], or an otherwise unscheduled visit to or from medical personnel for any reason, 
including emergency room visit s). This information will be recorded in the CRF/paper Expedited 
Adverse Events Report as applicable/in the eCRF.  
Assessment of Outcomes  
The investigator will assess the outcome of all unsolicited AEs (including SAEs) recorded during 
the study as:  
• Recovere d/resolved.  
• Recovering/resolving.  
• Not recovered/not resolved.  
• Recovered with sequelae/resolved with sequelae.  
71
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Reporting, Follow -up, and Assessment of AEs  
Recording AEs and SAEs  
All AEs and SAEs should be recorded into the appropriate section of the eCRF, irrespective of intensity or 
whether or not they are considered intervention -related.  
AE and SAE Recording  
• The participants’ parent (s)/LAR (s) will be instructed to contact [CONTACT_285152].  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (e.g., 
hospi[INVESTIGATOR_1088], laboratory and diagnos tics reports) relative to the event. The investigator will then 
record all relevant information regarding an AE/SAE in the eCRF. The investigator is not allowed to send 
photocopi[INVESTIGATOR_10914]’s medical records to either the sponsor or IQVIA instead  of appropriately 
completing the eCRF. However, there may be instances when copi[INVESTIGATOR_285104].  In this instance, all participant identifiers will be blinded on the copi[INVESTIGATOR_285105] s prior to submission to the sponsor or IQVIA.  
• The investigator will attempt to establish a diagnosis pertaining to the event based on signs, symptoms, 
and/or other clinical information. In such cases, the diagnosis should be documented as the AE/SAE and n ot 
the individual signs/symptoms.  
 
The Use of eDiary /personal electronic device app  
An eDiary will be used in this study to capture solicited administration site or systemic events. The participant s’ 
parent(s)/LAR(s) should be trained on how and when to complete the eDiary /enter information into the app. 
Anyone who measures administration site or systemic events and who will record the event in the eDiary /app 
should be trained on using the eDiary /app. This training must be documented in the participant ’s source 
documents. If any individual other than the participant’s parent(s)/LAR(s) is making entries in the eDiary/app , 
their identity must be documented in the eDiary/ app/participant’s source documents.  
 
Time Period for Collecting and Recording of AEs and SAEs  
All solicited administration site events  that occur during 4 days (Day 1 to Day 4), and solicited systemic events 
that occur during 15 days (Day 1 to Day 15)  or 43 days (Day 1 to Day 43), following administration of the  study 
intervention , must be recorded into the eDiary /personal electronic device app, irrespective of intensity. 
Unsolicited events occurring from Day 1 to Day 43 and SAEs occurring up the end of the study should be 
recorded into the appropriate section of the eC RF, irrespective of intensity or whether or not they are considered  
vaccination -related.  
 
72
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Follow -up of AEs and SAEs  
After the initial AE/SAE or any other event of interest for the study, the investigator is required to proactively 
follow each participant at subsequent visits/contacts. All SAEs will be followed until the event is resolved, 
stabilized, or otherwise explained or the participant is lost to follow -up. 
Other non -serious AEs must be followed until the last contact [CONTACT_285153] -up. 
Follow -up During the Study  
AEs documented at a previous visit/contact [CONTACT_103736]/not resolved or recovering/resolving 
will be reviewed at subsequent visits/contacts until the last visit/contact [CONTACT_167577] t. 
If the participant dies during participation in the study or during a recognized follow -up period, IQVIA will be 
provided with any available post -mortem findings, including histopathology.  
Follow -up After the Participant is Discharged from the Study  
The investigator will provide any new or updated relevant information on previously reported SAE to IQVIA 
using electronic Expedited AE Report as applicable. The investigator is obliged to perform or arrange for the 
conduct of supplemental clinical examinatio ns/tests and/or evaluations to elucidate the nature and/or causality of 
the AE or SAE as fully as possible.  
Updating of SAE Information After Removal of Write Access to the Participant’s eCRF  
When additional SAE information is received after removal of write access to the participant’s eCRF, new or 
updated information should be recorded on the appropriate paper report, with all changes signed and dated by [CONTACT_1275]. The updated report sh ould be faxed to IQVIA as described within the timeframes specified in 
Section  8.3.1 . 
 
Events Requiring Expedited Reporting to IQVIA : 
SAE (s) throughout the study  
• Once the investigator or designee become aware that study participant(s) have experienced an SAE, the 
investigator or designated study staff must complete information in the electronic Expedited AE Report in 
the eCRF WITHIN 24  HOURS.  The report will always be completed as thoroughly as possible with all 
available details of the event.  
• Even if the investigator does not have all information regarding an SAE, the report should still be completed 
within 24 hours. Once additional relevant information is received, the report should be updated WITHIN 24 
HOURS. The investigator will always provide an assessment of causality at the time of the initial report.  
• Refer to  Section  8.3.1  for the details on timeframes for reporting of SAEs.  
Grade 3 unsolicited AE(s) at least possibly related to vaccination  for the first 200 study participants  
through their Day 43 follow -up: 
• Once the investigator or designee become aware that study participant(s) have experienced a  Grade [ADDRESS_348252] complete information in the AE form in the eCRF WITHIN  24 HOURS. The AE form will always 
be completed as thoroughly as possible with all available details of the event.  
• Even if the investigator does not hav e all information  regarding a Grade [ADDRESS_348253] possibly related to vaccination , the AE form  should still be completed within 24 hours. Once additional 
relevant information is received, the AE form should be updated WITHIN 24  HOURS. The investigator will 
always provide an assessment of causality at the time of the initial completion of the AE form . 
• Refer to  Section  8.3.1  for the details on timeframes for reporting of AE (s). 
 
SAE Reporting to IQVIA via an Electronic Data Capture Tool  
• The primary mechanism for reporting an SAE to IQVIA will be the electronic Data Capture (EDC) Tool . 
73
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 • If the EDC is unavailable for more than 24 hours, then the study center  will use the paper Expedited AE 
Report.  
• The study center  staff will enter the SAE data into the EDC as soon as it become available.  
• After the study is completed at a given site, the ED C will be taken offline to prevent the entry of new data or 
changes to existing data.  
• If a study center  receives a report of a new SAE from a participant or receives updated data on a previously 
reported SAE after the EDC has been taken offline, then the study center  can report this information on a 
paper Expedited AE Report (see the next section) or to the M edical Monitor  by [CONTACT_648].  
• Contacts of the Medical Monitor for SAE reporting can be found in the S RM. 
 
Back up SAE Reporting to IQVIA via Paper (in Case of EDC Failure)  
• Fax transmission of the SAE paper Expedited AE Report is the preferred method to transmit this information 
to the M edical Monitor . 
• In rare circumstances and in the absence of Fax equipment, notification by [CONTACT_285154] a copy 
of the Expedited AE Report sent by [CONTACT_22855].  
• Initial notification via phone does not replace the need for the investigator to complete and sign the 
Expedited AE Report within the designated reporting timeframes.  
• Contacts of th e Medical Monitor for SAE reporting can be found in the S RM. 
Definitions of Medical Device Adverse Events and Adverse Device Effects  
A Medical Device AE  is: 
Any untoward medical occurrence, in a clinical study participant, users, or other persons, temporally associated 
with the use of study intervention  whether or not considered related to a medical device. An AE can therefore be 
any unfavorable and unintended  sign (including an abnormal laboratory finding), symptom, or disease (new or 
exacerbated) temporally associated with the use of a medical device. This definition includes events related to the 
medical device or comparator and events related to the procedu res involved.  
An Adverse Device Effect (ADE)  is: 
Any AE related to the use of a medical device. This definition includes any AE resulting from:  
• insufficient or inadequate instructions for use (i.e., user error), or  
• any malfunction of a medical device, or  
• intentional misuse of the medical device.  
74
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.[ADDRESS_348254]  
A Medical Device SAE is Any SAE that:  
a. Led to death  
b. Led to serious deterioration in the health of the participant, that either resulted in:  
• A life -threatening illness or injury. The term “life -threatening” in the definition of “serious” refers to an 
event in which the participant was at risk of death at the time of the event. It does not refe r to an event, 
which hypothetically might have caused death, if it were more severe.  
• A permanent impairment of a body structure or a body function.  
• Inpatient or prolonged hospi[INVESTIGATOR_059]. Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a 
procedure  required by [CONTACT_760], without serious deterioration in health, is not considered an SAE.  
• Medical or surgical intervention to prevent life -threatening illness or injury or permanent impairment to 
a body structure or a body function . 
c. Is a suspected tran smission of any infectious agent via a medicinal product  
A Serious Adverse Device Effect (SADE) is:  
• A SADE is defined as an ADE that has resulted in any of the consequences characteristic of a serious adverse 
event.  
• Any device deficiency that might have led to an SAE if appropriate action had not been taken, intervention 
had not occurred, or circumstances had been less fortunate.  
An Unanticipated SADE ([LOCATION_003]DE) is:  
• An [LOCATION_003]DE (also identified as UADE in US Regulations 21 CFR 813.3),  is a SADE that by i ts nature, 
incidence, severity or outcome has not been identified in the current version of the IB.  
 
Recording and Reporting of Device Deficiencies  
• Device deficiencies must be reported to IQVIA within 24 hours after the investigator determines that the 
event meets the definition of a device deficiency.  
• Fax transmission of the paper “Medical device or combination product with device deficiency/incident report 
form” is the preferred method to transmit this information to IQVIA.  
• In rare circumstances an d in the absence of Fax equipment, notification by [CONTACT_285154] a copy 
of “Medical device or combination product with device deficiency/incident report form” sent by [CONTACT_19515].  
• IQVIA will review all device deficiencies a nd determine and document in writing whether they could have 
led to an SAE. These device deficiencies will be reported to the regulatory authorities and IRBs /IECs  as 
required by [CONTACT_2091].  
  
75
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Appendix  5 Protocol Amendment History  
The Protocol Am endment Summary of Changes Table  for the current amendment  
(Amendment  3) is located directly before the Table  of Contents (TOC).  
Detailed description of the changes in Protocol Amendment 3:  
(additional  text in  bold  and italic ; deletions in strikethrough ) 
 
General Changes:  
• Throughout the protocol, the reference that the study will be conducted in the US, was 
removed. Rationale: the study will be expanded to the countries outside the US.  
• A note, “ if applicable ” is added to Prevnar 13 vaccinati on where necessary.  
• M-M-RVaxPro was mentioned as a name [CONTACT_285164].  
• Added “ approximately ” to “50 participants in each group”, whenever mentioned.  
• Through the protocol, it is noted that the IEC, besides IRB, will also be an entity 
overseeing the ethical conduct of the study. The text regarding EU -specific regulations 
was also added as applicable.  
• “Study as a whole” was replaced with “ country ” as a minimization factor for analysis.  
• Added the note/footnote , Participants recruited outside of the US will be 
co-administered with MMR, Havrix, and in some countries, with Prevnar 13. 
Prevnar  13 will only be administered to participants enrolled in the Unite d States and 
in countries where pneumococcal conjugate vaccine is recommended at 12 -15 months 
as per national immunization schedule , when applicable (throughout the protocol and in 
the Schedule of Activities).  
• Added the note,  At the end of the study or sho rtly after the study, depending on the 
vaccines’ availability, [COMPANY_004] will provide a second dose of Varivax and/or Havrix to 
participants enrolled in non -US countries if local health departments do not routinely 
provide varicella and/or hepatitis A vaccine. S tudy participants who do not achieve the 
pre-specified seroresponse threshold criteria will be re -vaccinated with a dose of 
Varivax (throughout the protocol and in the Schedule of Activities).  
• Title Page, Sponsor’s Signature [CONTACT_3490], Header: updated the numbe r of the protocol 
amendment from 2.0 to 3.0. Added the date of the amendment as applicable.   
• Title Page:  added the clinical trial registry number s. 
Note: In various sections, the repeated changes with the same or similar wording are not detailed 
if they ha ve been made clear earlier.  
Note: The minor changes such as for grammar/readability/correction of typos are not listed.  
1.0, Protocol Summary  
Rationale: Participants recruited outside of the US will be co -administered with MMR , 
Havrix, and in some countries, with Prevnar 13. Outside the US, Prevnar 13 will only be 
76
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 administered in countries where pneumococcal conjugate vaccine is recommended at 
12-15 months as per national immunization schedule. At the end of the study or shortly  after 
the study, depending on the vaccines’  availability, [COMPANY_004] will provide a second dose of Varivax 
and/or Havrix to participants enrolled in non -US countries if local health departments do not 
routinely provide varicella and/or hepatitis A vaccine. Study  participants who do not achieve 
the pre -specified seroresponse threshold criteria will be re -vaccinated with a dose of Varivax.  
Overall Design:  Participants recruited outside of the US will be co administered with MMR, 
Havrix, and in some countries, with Prevnar 13. Outside the US, Prevnar [ADDRESS_348255] 60 days prior to study entry.  
1.3, Schedule of Activities  
Added the information about Prevnar 13  administration at non -US sites.  
Added the row with about the conditional administration of the second dose of Varivax  and/or 
Havrix . Noted that, The administration of the second dose of Havrix and Varivax is not part of 
the study procedures, however, the administration of the second dose ( or the date of the 
planned visit for administration) should be recorded in the eCRF.  
2.1, Study Rationale  
Same changes as in Protocol Summary . 
2.3.2, Risk Mitigation Strategies  
The burden of the study for the participant will be minimized as much as possib le. For taking 
blood samples, [ADDRESS_348256] should be performed. If the investigator/designee is not 
successful after the third attempt, the investigator/designee will make no further attempts. A 
local numbing cream or patch will also be offered at th e discretion of the investigator prior to 
blood sampling, to minimize pain when blood samples are drawn.  
[COMPANY_004]/IQVIA will immediately notify the investigators if any additional safety or toxicology 
information becomes available during the study.  
This study will be performed in compliance with the protocol, ICH GCP, EU CTR, and 
applicable regulatory requirements. Aspects of the study concerned with the investigational 
medicinal products will meet the requirements of European Union – Good Manufacturing 
Practice, as applicable.  
4.1, Overall Design  
Same changes as in Protocol Summary  and Study Rationale . 
4.2.1, Rationale for Clinical Study Population  
77
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.[ADDRESS_348257] varicella in early years of life is 
recommended to prevent development of chickenpox in older age.  
The incidence of varicella has decreased significantly since implementation of the national 
varicella vaccination program in 1996 in the US [ CDC, 2015 ]. 
In the US, the incidence of varicella has decreased significantly since implementation of the 
national varicella vaccination program in 1996 [ CDC, 2015 ]. 
Adolescents (≥13 years) and adults should receive 2 doses of the single -antigen varicella vaccine 
4 to 8 weeks apart.  
[IP_ADDRESS], Comparator  
Varivax has proven effectiveness. It is approved in more than 70 countries.  
[IP_ADDRESS], Co -administered vaccines  
MMR , Havrix , and Prevnar [ADDRESS_348258] dose 
administered at 12 to 15 months of age and the second dose administered between 4 and 6 years 
of age.  In EU, vaccination with 2 doses of varicella vaccine is recommended in different 
countries according to local and regional public health guidelines.  
5.1, Inclusion Criteria  
• Only for US participants and participants in countries where pneumococcal conjugate 
vaccine is recommended at 12 -15 months of life as per national immunization sched ule: 
Participants who previously received the primary series of pneumococcal conjugate vaccine 
in their first year of life with the last dose at least 60 days prior to study entry.  
6.1, Study Interventions Administered  
Table  7, Study Intervention Administered  
Changed the number of dose s for Varivax  and Havrix  from 1 to 2 . 
Added the footnotes:  
**Prevnar 13 will only be administered to participants enrolled in the [LOCATION_002] and in 
countries where pneumococcal conjugate vaccine is rec ommended at 12 to 15 months as per 
national immunization schedule  
*** For non -US participants only. At the end of the study or shortly after the study, depending 
on the vaccines’ availability, [COMPANY_004] will provide a second dose of Havrix and/or Varivax in 
78
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 coun tries where they are not routinely provided. The administration of the second dose of 
Havrix and Varivax is not part of the study procedures.  
6.2, Preparation/Handling/Storage/Accountability  
Varivax will be stored at −15°C to −30°C (+5°F to −22°F) in the U S and at +2°C to +8°C 
(+36°F to +46°F) in the rest of the world.  (Note: Refrigerated Varivax vaccine will be used at 
non-US sites, while frozen Varivax vaccine will be used at sites in the US and other countries 
with frozen formulation).  
Temperature excurs ions, For VNS Diluent:  
Any temperature excursion outside the range of 0+1.5°C to +8.0+8.4°C (for +2 to +8°C/+36 to 
+46°F label storage condition).  
In case of temperature excursion below +2.0°C down to 0.0°C impacting IMPs, there is no need 
to report in (e)TDF, but adequate actions must be taken to restore the +2 to +8°C/+36 to +46°F 
label storage temperature  
• For Varivax Diluent, Varivax antigen with refrigerated formulation  and all other products 
(Prevnar 13 , Havrix , MMR)  
• For Varivax  antigen in the US and other countries with frozen formulation  
Any temperature excursion above − 2015.0°C (for −20°C/−4°F label storage condition)  
impacting study interventions must be reported in the appropriate (e)TDF.  
6.3.2, Randomization to Study Intervention, 6.3.3, Intervention Allocation to Participants  
The study as a whole  country and center will be used as minimization factors for randomiza tion. 
6.6, Continuing Access to Study Intervention after the End of the Study  
There will be no continuing access to study intervention after the end of the study.  At the end of 
the study or shortly after the study, depending on the vaccines’ availability, [COMPANY_004] will provide a 
second dose of Varivax and/or Havrix to participants enrolled in non -US countries if local 
health departments do not routinely provide varicella and/or hepatitis A vaccine.  
8.1.3,  Immunological Correlates of Protection  
..while all childr en are expected to receive a second dose of the varicella vaccine as per ACIP 
recommended schedule at 4 to 6 years of age [ACIP, 2007].  
9.4.1, Statistical Analysis Plan  
There is no intention to conduct specific analyses investigating the relationship betwe en the 
gender of the participants and the immunogenicity and safety of the study vaccine. The ratio 
79
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 of male to female participants recruited into this study is expected to be in line with the 
demographics of the population aged 12 to 15 months of age.  
Appe ndix  1 Abbreviations and the Glossary of Terms  
IEC Independent Ethics Committee  
MMR  Measles, mumps, and rubella vaccine  
Appendix 2  Regulatory, Ethical, and Study Oversight Considerations  
• The investigator will be responsible for the following:  
− Providing ove rsight of the conduct of the study at the site and adherence to 
requirements of 21 Code of Federal Regulations (CFR), ICH guidelines, the 
IRB/IEC , European regulation 536/2014 for clinical studies (if applicable) , and all 
other applicable local regulations . 
Amendment  2.0 (15 -November -2021)  
Overall Rationale for the Amendment:  
This protocol was amended at the request of CBER to  add drowsiness, loss of appetite, 
irritability, and general rash (not varicella -like) to the list of solicited systemic events. In 
addition, the reporting instructions for the Grade 3 unsolicited events ( at least possibly related to 
vaccination for the fi rst 200 study participants through their Day 43 follow -up) were updated.  
Description of the Most Important Changes in Amendment 2  
Section  # and Name  [CONTACT_11029]  
1.[ADDRESS_348259] study intervention: general rash 
(not varicella -like). 
3.0 Objectives and 
Endpoints  Included general rash (not varicella -like) in the endpoint 
related to solicited systemic event collected from Day 1 to Day 
43. 
Added the endpoint of the p ercentage of participants reporting 
each solicited systemic event in terms of drowsiness, loss of 
appetite, and irritability from Day 1 to Day 15. 
4.0 Overall Design  Added the collection of solicited systemic events of 
drowsiness, loss of appetite, and irritability  from Day 1 to Day 
15 and clarified that f ever, varicella -like rash (including 
injection site varicella -like rash) and general rash (not 
varicella -like) will be collected from Day 1 to Day 43.  
80
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Section  # and Name  [CONTACT_11029]  
6.2 Preparation/Handling/
Storage/Accountability  Removed the mention of Varivax antigen  from the products to 
be stored between 2.0°C to +8.0°C . The Varivax  antigen 
used in the study is a 
frozen one and not a 
refrigerated one . 
Appendix 4 Adverse 
Events: Definitions and 
Procedures for Recording , 
Evaluating, Follow -up, 
and Reporting  Added general rash (not varicella -like), drowsiness, loss of 
appetite, irritability to the list of solicited systemic events.  These adverse reactions 
are commonly 
described in the setting 
of vaccine trial s in 
children over 
12 months of age . 
Added intensity scales grades for drowsiness, loss of appetite, 
irritability and general rash (not varicella -like).  To provide the 
instructions for 
assessment of intensity 
of the newly added 
events . 
Removed the requirement for the investigator to confirm the 
review of an SAE/Grade [ADDRESS_348260] 200 study participants 
through their Day 43 follow -up by [CONTACT_43078] “reviewed” box 
in the electronic  report . For the alignment with 
the e lectronic case 
report form . 
Updated the reporting of Grade [ADDRESS_348261] 200 study 
participants through their Day 43 follow -up.  
Detailed description of the changes in Protocol Amendment 2:  
(additional  text in  bold +italic ; deletions in strikethrough ) 
1.3, Schedule of Activities  
Table 3 Schedule of Activities  
The added cells and text:  
Recording of solicited systemic 
events (drowsiness, loss of appetite 
and irritability) from Day [ADDRESS_348262] 
study intervention administration  ○ ○ ○   See Section  8.3 and 
Appendix  4 
Recording of solicited systemic 
events  (fever, varicella -like rash 
[including injection site 
varicella -like rash] and general rash 
[not varicella -like]) from  Day 1-[ADDRESS_348263] study intervention administration  ○ ○ ○ ○  See Section  8.[ADDRESS_348264] study intervention 
administration  ● ● ● ●  See Section 8.3  for details  
and Appendix  4 for 
definitions  
 
3.0, Objectives and Endpoints  
81
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Table 5 , Study Objectives and Endpoints  
The following change was made:  
• To evaluate safety and reactogenicity following 
administration of VNS and VV vaccines  Solicited events  
• Percentage of participants reporting each solicited 
administration site event in terms of injection site 
redness, pain and swelling within 4 days (Day  1 to 
Day 4) post -dose of VNS vaccine or VV vaccine  
• Percentage of participants r eporting each solicited 
systemic event in terms of fever, and varicella -like 
rash†, and general rash (not varicella -like) within 
43 days (Day  1 to Day  43) post -dose of study 
interventions  
• Percentage of participants reporting each solicited 
systemic event in terms of drowsiness, loss of 
appetite , and irritability within 15 days (Day  1 to 
Day 15) post -dose of study interventions** 
Unsolicited adverse events (AEs)*** 
• Percentage of participants reporting unsolicited AEs 
within 43 days (Day  1 to Day  43) p ost-dose of 
study interventions** 
Serious adverse events (SAEs)  
• Percentage of participants reporting SAEs 
post-dose of study interventions** up to the end of 
study  
4.1, Overall Design  
Figur e 1, Study Design Overview  
The obsolete  figure was replaced with the  new one.  The footnote was updated.  
The obsolete figure:  
82
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
  
The n ew figure:  
 
VNS_Low, VNS_Med, and VNS_High vaccine = VNS vaccine in low, medium, and high potency; VV_Lot 1 and 
VV_Lot 2 = VV vaccine in 2 lots  
a VV_Lot 1 and VV_Lot 2 groups will be analyzed as pooled groups  
83
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.[ADDRESS_348265] (by [CONTACT_285118]) for the safety follow -up will take place [ADDRESS_348266]-dose of study interventions  
c Study interventions: VNS vaccine (investiga tional vaccine) or VV vaccine (Varivax, comparator vaccine); 
M-M-R II, Havrix , and Prevnar 13  (co-administered vaccines)  
d Recording in the electronic Case Report Form  
e Blood sampling for anti -glycoprotein E enzyme -linked immunosorbent assay  
f Independent  Data Monitoring Committee review details are provided in  Section 8.2.[ADDRESS_348267] -vaccination safety data may be a virtual visit  
h Safety call to remind completion of the eDiary/app and address any potential early post -vaccination safety concerns  
*Drowsiness, loss of appetite, irritability  
**Fever, varicella -like rash (including injection site varicella -like rash) and general rash (n ot varicella -like) 
6.2, Preparation/Handling/Storage/Accountability  
• For Varivax Antigen Diluent and All Other Products ( Prevnar 13 , Havrix , M-M-R II) 
[IP_ADDRESS], Study Holding Rules  
Figure 2  Communication Flow: Identification of Holding Rules by [CONTACT_285155]:  
 
New figure:  
84
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
  
CRDL = Clinical Research and Development Lead; GSB = Global Safety Board; IDMC = Independent Data 
Monitoring Committee;  IVRS  = Interactive Voice Response System; SRT = Safety Review Team  
*Investigators are responsible to inform the Institutional Review Board if a holding rule is met.  
9.5.1, Sequence of Analyses  
Apart from the analyses to be performed in support to the IDMC , a statistical analysis and a 
report  including safety and final immunogenicity data for all participants up to Day  43 time 
point is planned. Following unblinding for the analysis up to Day  43, accessibility to group 
attribution will be limited so that the  study center blinding is maintained until the 6 -month safety 
follow -up is completed for all participants.  
Appendix 4, Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting  
Solicited Events will include the followin g: 
c) Solicited administration site events  
The following administration site events will be solicited for toddlers 12 to 15 months of age at the time of the 
study intervention:  
• Pain 
• Redness  
• Swelling  
d) Solicited systemic events  
The following systemic events will be solicited for toddlers  12 to 15 months of age at the time of the study 
intervention : 
85
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 • Fever  
• Varicella -like rash  (including injection site varicella -like rash ) 
• General rash (not varicella -like) 
• Drowsiness  
• Loss of appetit e 
• Irritability  
Note: participants’ parent(s)/LAR(s) will be instructed to measure and record body temperature in the evening 
using the temperature measuring device provided by [CONTACT_23983]. The recommended route of temperature measurement 
will be the axilla. Should additional temperature measurements be performed at other times of day, participants’ 
parent(s)/LAR(s) will be instructed to record the highest temperature in the eDiary/personal electronic device 
app. 
b) Solicited systemic events  
The following system ic events will be solicited for children toddlers  12 to 15 months of age at the time of the 
study intervention : 
• Fever  
• Varicella -like rash (including injection site varicella -like rash)  
• General rash (not varicella -like) 
• Drowsiness  
• Loss of appetite  
• Irritability   
86
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Table  15 Intensity Scales for Solicited Symptoms in Toddlers (12 to 15 Months of Age)  
Toddler (12 to 15 months of age)  
Adverse Event  Intensity Grade  Parameter  
Pain at injection site  0 None  
1 Mild: Minor reaction to touch  
2 Moderate: Cries/protests on touch  
3 Severe: Cries when limb is moved/spontaneously painful  
Redness at injection site  Greatest surface diameter in mm  
Swelling at injection site  Greatest surface diameter in mm  
Fever* Temperature in °C/°F  
Varicella -like rash** Number of lesions  
General rash (not 
varicella -like)  0 None  
1 Mild: Rash which is easily tolerated by [CONTACT_2252], causing minimal 
discomfort and not interfering with everyday activities  
2 Moderate: Rash which is sufficiently discomforting to interfere with 
normal everyday activities  
3 Severe: Rash which prevents normal, everyday activities (in a 
young child, such an AE would, for example, prevent attendance at 
school/day care and would cause the parent(s)/LAR(s) to seek 
medical advice)  
Drowsiness  
 0 Behavior as usual  
1 Mild: Drowsiness easily tolerated  
2 Moderate: Drowsiness that interferes with normal activity  
3 Severe: Drowsiness that prevents normal activity  
Loss of appetite  
 0 Appetite as usual  
1 Mild: Eating less than usual/no effect on normal activity  
2 Moderate: Eating less than usual/interferes with normal activity  
3 Severe: Not eating at all  
Irritability  
 0 Behavior as usual  
1 Mild: Crying more than usual/no effect on normal activity  
2 Moderate: Crying more than usual/interferes with normal activity  
3 Severe: Crying that cannot be comforted/prevents normal activity  
*Fever is defined as temperature ≥ 38.0°C (100.4°F) by [CONTACT_28414]. The preferred location for measuring temperature 
will be the axilla.  
**A typi[INVESTIGATOR_285103] -like rash manifests as a rash/lesions that may appear within 2 weeks (or sometimes later) after 
the varicella vaccination. Lesions may contain spots, bumps, blisters, or  crusts. Refer to the S tudy Reference 
Manual  for detailed varicella -like rash guidelines.  
Time Period for Collecting and Recording of AEs and SAEs  
All solicited administration site  and solicited systemic events  that occur during 4  days (Day  1 to Day  4), and 
solicited systemic events that occur during 145 days (Day 1 to Day 15) andor 43 days (Day  1 to Day  43), 
respectively , following administration of the study intervention must be recorded into the eDiary/persona l 
electronic device app, irrespective of intensity or whether or not they are considered intervention -related . 
Unsolicited events occurring from Day  1 to Day  43 and SAEs occurring up the end of the study should be 
recorded into the appropriate section of t he eCRF, irrespective of intensity or whether or not they are considered 
vaccination -related.  
 
Events Requiring Expedited Reporting to IQVIA:  
SAE(s) throughout the study  
87
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 • Once the investigator or designee become aware that study participant(s) have exper ienced an SAE, the 
investigator or designated study staff must complete information in the electronic Expedited AE Report in 
the eCRF WITHIN 24  HOURS. The report will always be completed as thoroughly as possible with all 
available details of the event.  
• Even if the investigator does not have all information regarding an SAE, the report should still be completed 
within 24 hours. Once additional relevant information is received, the report should be updated WITHIN 24 
HOURS. The investigator will always provid e an assessment of causality at the time of the initial report.  
• The investigator will be required to confirm the review of the SAE causality by [CONTACT_43078] “reviewed” box in 
the electronic Expedited AE Report within 72 hours of submission of the SAE.  
• Refer  to Section  8.3.1  for the details on timeframes for reporting of SAEs.  
Grade 3 unsolicited AE(s) at least possibly related to vaccination  for the first 200 study participants through 
their Day 43 follow -up: 
• Once the investigator or designee become aware that study participant(s) have experienced a Grade [ADDRESS_348268] complete information in the electronic E xpedited AE Report  AE form  in the eCRF WITHIN 
24 HOURS. The report AE form  will always be completed as thoroughly as possible with all available 
details of the event.  
• Even if the investigator does not have all information regarding a Grade [ADDRESS_348269] possibly related to vaccination, the report AE form  should still be completed within 24 hours. Once 
additional relevant information is received, the reportAE form  should be updated WITHIN 24 HOURS. The 
investigator will always provide an assessment of causality at the time of the initial report completion of the 
AE form . 
• The investigator will be required to confirm the review of the Grade 3 unsolicited AE(s ) causality by [CONTACT_90649] “reviewed” box in the electronic Expedited AE Report within 72 hours of submission of the Grade 3 
unsolicited AE(s).  
• Refer to  Section  8.3.1  for the details on timeframes for reporting of AE(s).  
Amendment  1.0 (08-October -2021)  
Overall Rationale for the Amendment:  
This protocol was amended at the request of CBER to add early safety time  point checks, to 
exclude participants with a history of SARS -CoV -2 (severe acute respi[INVESTIGATOR_18960] 2) infection who remain symptomatic, to exclude susceptible high -risk individual 
members of the potential participant’s household, to clarify that varicella -like-rash includes 
injection site varicella -like rash, to include holding rules for the first 200 study participants 
enrolled and to revise the grading to assess the severity of the varicella -like rash.  
Section  # and 
Name  [CONTACT_11029]  
1.[ADDRESS_348270] -
vaccination safety data, respectively.  
88
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Section  # and 
Name  [CONTACT_285165]  [ADDRESS_348271]-vaccination safety data, respectively.  
5.2 Exclusion  
Criteria  Inserted new criterion  To exclude participants with susceptible 
high-risk individuals in their household, in case 
of varicella transmission  
5.2 Exclusion  
Criteria  Inserted new criterion  To exclude participants with a history of 
SARS -CoV -2 infection who  remain 
symptomatic  
8.1.3 
Immunological 
Correlates of 
Protection  Added sentence “ Study participants 
who do not achieve the pre -specified 
seroresponse threshold criteria will be 
re-vaccinated with a dose of Varivax .” To specify when re -vaccination should t ake 
place.  
8.2.[ADDRESS_348272] the inclusion of 
holding rules  To further clarify procedures for safety 
monitoring by [CONTACT_285156]  
8.2.3 Study 
Holding Rules and 
Safety Monitoring  Added Section  [IP_ADDRESS] and Table  9, 
both titled Study Holding Rules  To include holding rules as this is considered as 
a first time in human study  
8.2.3 Study 
Holding Rules and  
Safety Monitoring  Added Section  [IP_ADDRESS], Outcome of 
Safety Evaluation  To explain what will happen following the 
outcome of the review by [CONTACT_285157] 200 participants  
Appendix  4 
Adverse Events: 
Definitions and 
Procedures for 
Recording, 
Evaluating, Follow -
up, and Reporting  Updated reporting requirements to 
include events listed in Holding Rules , 
clarification that injection site 
varicella -like rash is included as 
solicited systemic event, update of 
grading for varicella -like rash and fever  
 To include holding rules as this is consid ered a 
first time in human study , clarify AE 
information  
Appendix  5 
Protocol Inserted new appendix  To track protocol amendment history  
89
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Section  # and 
Name  [CONTACT_285166]-substantial changes such as editorial changes and administrative changes are not included in 
this list. 
Detailed description of the changes in Protocol Amendment 1:  
(additional  text in  bold  and italic ; deletions in strikethrough ) 
 
1.1, Synopsis  (Overall Design) : 
Randomization to one of the 5 groups will be performed in a 2:2:2:1:1 ratio prior to inter vention. 
There will b e 23 study visits, at Day  1 (intervention),  Day 15 (virtual or in -person),  and Day  43, 
as well as a [ADDRESS_348273], at Day  2-3 and  Day 181, respectively . 
1.2, Schema: Third visit and safety call added to schema.  
Added the following to Schema footnotes:  
g Visit  [ADDRESS_348274] -vaccination safety data may be a virtual visit.  
h Safety call to remind completion of the eDiary/app and check on potential early post -vaccination safety  events  
1.3, Schedule of Activities:  Third visit and safety call added.  
Age 12-[ADDRESS_348275]  Visit  1 Safety call  Visit  2† Visit  [ADDRESS_348276]   
Time  points  Day 1 Day 2-3 Day 15 Day 43 Day 181  
Informed consent  ●     See Appendix  2 for 
details  
Check 
inclusion/exclusion 
criteria  ●   
  See Section  5.[ADDRESS_348277] demographic 
data ●     See Section  [IP_ADDRESS]  
for details  
Medical history  ●     See Section  [IP_ADDRESS]  
for details  
Vaccination history  
(protocol -specific 
vaccines including PCV)  ●   
  See Section  [IP_ADDRESS]  
for details  
See Section  5.1 for 
details  
Physical examination  ●     See Section  [IP_ADDRESS]  
for details  
Randomization  ○     See Section  6.3.2  for 
details  
Study interventions   See Appendix  1 for 
the definition  
90
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.[ADDRESS_348278]  Visit  1 Safety call  Visit  2† Visit  [ADDRESS_348279]   
Time  points  Day 1 Day 2-3 Day 15 Day 43 Day 181  
Check contraindications, 
warnings and 
precautions to study 
intervention 
administration  ○   
  See Section  [IP_ADDRESS]  
for details  
Check criteria for 
temporary delay for 
enrollment and study 
intervention 
administration  ●   
  See Section  5.5 for 
details  
Study group and 
treatment number 
allocation   ○   
  See Section  6.3.3  for 
details  
Body temperature before 
study intervention 
administration  
●   
  The preferred 
location for 
measuring 
temperature will be 
the axilla. Fever is 
defined as body 
temperature ≥  
38.0°C/100.4°F  
Study intervention (VNS 
vaccine/VV vaccine, and 
M-M-R II, Havrix , and 
Prevnar 13 ) 
administration  
●   
  Study participants 
who do not achieve 
the pre -specified 
seroresponse 
threshold criteria 
will be re -vaccinated 
with a dose of 
Varivax  The 
investigator  will 
assess if re -
vaccination with 
Varivax  is needed 
for the children who 
fail to serorespond to 
varicella virus (i.e., 
post-vaccination 
anti-gE antibody 
concentration is 
<300 mIU /mL at 
Day 43) after the 
Day 43 
immunogenici ty 
results  are available . 
Recording of 
administered study 
treatment number  ●   
   
91
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.[ADDRESS_348280]  Visit  1 Safety call  Visit  2† Visit  [ADDRESS_348281]   
Time  points  Day 1 Day 2-3 Day 15 Day 43 Day 181  
Distribute 
eDiaries/download the 
app 
○   
  An eDiary/personal 
electronic device 
application (app) 
will be used to 
capture solicited 
administration site or 
systemic events. The 
participant’s 
parent(s)/LAR(s) 
should be trained on 
the use of the 
eDiary/app. See 
Appendix  4 for 
details  
Laboratory assessment  
Blood sampling for 
antibody determination 
(~3 mL)    
●  See Section  8.1.[ADDRESS_348282] any concomitant 
medications/vaccinations  ● ● ● ●  See Section  6.[ADDRESS_348283] any intercurrent 
medical conditions      ●  See Section  9.[ADDRESS_348284] for safety 
follow -up  ●  
 ● Or any other 
convenient 
procedure  
Recording of solicited 
administration site 
events from Day 1-[ADDRESS_348285] study intervention 
administration  ○ ○  
  Only events 
following the 
administered dose of 
VNS vaccine or VV 
vaccine will be 
solicited  
Safety follow -up with 
clinical staff to review 
post-vaccination safety 
data   
●    
Recording of solicited 
systemic events from 
Day 1-[ADDRESS_348286] study 
intervention 
administration  ○ ○ ○ ○  See Section  8.[ADDRESS_348287] study 
intervention 
administration  ● ● ● ●  See Section  8.3 for 
details and 
Appendix  4 for 
definitions  
eDiary/app completion 
reminder   ●     
Review of eDiaries/app 
data  ○ ● ●   
92
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.[ADDRESS_348288]  Visit  1 Safety call  Visit  2† Visit  [ADDRESS_348289]   
Time  points  Day 1 Day 2-3 Day 15 Day 43 Day 181  
Return of 
eDiaries/uninstall or 
disable the app     
○  See Section  8.5 for 
details  
Recording of SAEs  
● ● ● ● ● See Section  8.3 for 
details and 
Appendix  4 for the 
definition  
Recording of SAEs 
related to study 
participation, or to a 
concurrent [COMPANY_004] 
medication/vaccine  ● ● ● ● ● The collection and 
reporting period s 
start once the 
participant’s 
parent(s)/LAR(s)’s 
informed consent is 
obtained  
Study Conclusion      ● See Section  4.3 for 
the definition.  
†Visit  2 (Day  15) may be conducted in -person or virtually.  
Refer to the Study Reference Manual (SRM) /Pharmacy Manual  for the volume of the vaccine after reconstitution.  
 
Table  4 Intervals Between Study Visits  
Interval  Planned visit interval* Allowed interval range  
Visit  1→ Safety call  1 to 2 days  1 to 3 days 
Visit  1→Visit  2 14 days 14 to 19 days 
Visit  1→Visit  32 42 days  35 to 56 days  
Visit  1→ Safety follow -up contact  180 days  180 to 201 days  
Note: Whenever possible, the investigator should arrange study visits following the planned visit interval. Deviation 
from allowed interval between Visit  1 and Visit  23 will lead to elimination from the Per Protocol Set . 
2.3.2, Risk Mitigation Strategies:  
The blinded mon itoring of study data will be performed by [CONTACT_285113]’s designee/Contract 
Research Organization (IQVIA) (see study administrative structure in  Appendix  2 [Table  12]). 
Additional unblinded safety monitoring will be performed by [CONTACT_269395] (IDMC) . composed of clinical experts, independent of the study protocol and 
external to [COMPANY_004] and IQVIA, and an independent biostatistician . Frequent  Monthly  Safety 
Review Team (SRT) review will occur up to the completion of enrollment a nd vaccination of the 
first 200 participants, to monitor cumulative, blinded safety data (including serious and non -
serious AEs)  (see Section  8.2.3 ). In addition,  for the first 200 study participants through their 
93
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Day 43 follow -up, the following criteria w ould be applied, that would result in a pause in study 
activities, including dosing and enrollment : 
a. Any death at least possibly related to vaccination (refer to Section  8.3.3  for expedited 
reporting)  
b. ≥1 participant with SAE/s at least possibly related to v accination (refer to Section  8.3.3  
for expedited reporting)  
c. ≥[ADDRESS_348290] possibly 
related to vaccination, (refer to Section  8.3.[ADDRESS_348291]/ visit)  
Note: “similarity” of the events will be based on medical judgment.  
An enrollment pause is  also foreseen for the first IDMC review after 200 participants (50 in each 
group, considering pooled VV groups) are enrolled and vaccinated. The analysis will  take place 
once all [ADDRESS_348292] returned for their Day  43 visit (Visit  23) or have withdrawn from 
the study, within the allowed interval for the visit. A positive outcome  of the IDMC review of 
the Day 43 safety follow -up data of the 200 participants  will be a pre -requisite for the 
continuation of the study.  
Section  3, Objectives and Endpoints:  
† Includes injection site varicella -like rash . 
Section 4.1, Overall Design:  
There will be 23 in-person study visits: on Day  1, when the participants receive study 
intervention, on Day 15 (either in -person or virtually , for review of post -vaccination safety 
data), and on Day  43, when blood sampling for vaccine antibody testing will be performed . The 
third visit  There will also be [ADDRESS_348293], on Day 181; will be a safety follow -up contact  [CONTACT_285158]. The vi sits should occur within a pre -
defined visit window (see  Table 24). 
Section 5.2.1, Medical Conditions : 
• Participant with history of SARS -CoV-2 infection who is still symptomatic . 
Section 5.2.2, Prior and Concomitant Therapy : 
• Planned administration/administration of a vaccine not foreseen by [CONTACT_163543] 30 days before the dose and ending at 43 days after the dose of study 
interventions administration* (Visit  23) with the exception of inactivated influenza (flu) 
94
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 vaccine which may be given at any time during the study and administered at a different 
location than the study interventions.  
Any other age -appropriate vaccine may be given starting at Visit  23 and anytime thereafter.  
Section 5.2.4, Other Exclusions : 
• Participants with the following high -risk individuals in their household:  
o Immunocompromised individuals.  
o Pregnant women without documented history of varicella.  
o Newborn infants of mothers without documented history of varicella.  
o Newborn infants born <28 weeks of gestation.  
Section 6 .0, Study Intervention, Table 7, Study Interventions Administered:  
*Refer to the SRM /pharmacy manual  for the volume after reconstitution  
 
Section 8.1.3 , Immunological Correlates of Protection:  
Upon receiving the result, the investigator will assess if any step needs to be taken regarding the 
individual child, while all children are expected to receive a second dose of the varicella vaccine 
as per ACIP rec ommended schedule at 4 to 6 years of age ([ACIP, 2007 ]). Study participants 
who do not achieve the pre -specified seroresponse threshold criteria will be re -vaccinated with 
a dose of Varivax . 
Section 8.2.3 , Safety Monitoring and Study Holding Rules  
Besides safety monitoring by [CONTACT_285126]/Center Monitors (see the definition in  Appendix  1), 
an IDMC comprising of clinical experts and an independent biostatistician will provide safety 
oversight during the active vaccination period, through unblinded r eview of the cumulative 
safety data.  
Up to the completion of enrollment and vaccination of the first 200 participants  through their 
Day 43 follow -up, enrollment will be paused for an ad hoc IDMC review of the cumulative 
safety data if any of the holding ru les are met (See Section  [IP_ADDRESS] ). 
An enrollment pause is foreseen for the first IDMC review after 200 participants (50  in each 
group, considering pooled VV groups) are enrolled and vaccinated. A positive outcome of the 
IDMC review of the Day  [ADDRESS_348294] 
returned for their Day  43 visit (Visit  23) or have withdrawn from the study, within the allowed 
interval for the visit. A positive outco me of the IDMC review will be a pre -requisite for the 
continuation of the study.  
95
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.[ADDRESS_348295] 200 participants  through their Day 43 follow -up, to 
monitor cumulative, blinded, safety data (including serious and non -serious AEs). The blinded 
safety data review by [CONTACT_285159] [ADDRESS_348296] returned for their Day 43 visit ( Visit  32) or have withdrawn from the study, 
within the allowed interval for the visit.  
Section [IP_ADDRESS], Study Holding Rules  
The safety holding rules defined in  Table  [ADDRESS_348297] possibly related to study vaccination  ≥ 1 
2 Any SAE (s) considered at least possibly related to vaccination  ≥ 1 
3 Same or similar* Grade [ADDRESS_348298] possibly 
related to vaccination  ≥ 2 
AE = adverse event; IDMC = Independent Data Monitoring Committee; SAE = serious adverse event  
*based on medical judgment  
If the investigator becomes aware of a holding rule being met, he/she must suspend 
administration of the study intervention, pause  enrollment, and inform IQVIA immediately 
(e.g., holding rules 1 -3). Refer to  Appendi x [ADDRESS_348299] be followed  (Figure 2) . 
96
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Figure 2  Communication Flow: Identification of Holding Rules by [CONTACT_285160] [IP_ADDRESS]  Outcome of Safety Evaluation  
If a safety signal is observed during the safety evaluations, or if any of the holdin g rules is met 
for the first 200 participants, the IDMC Chair (or his/her representative) is responsible for the 
urgent communication to [COMPANY_004], including the rationale for the decision to put the study 
intervention administration on hold or not . 
If no safety signal is observed in the first [ADDRESS_348300] of the study on all groups or on selected groups.  
Refer to Section  [IP_ADDRESS]  for a flow chart for escalation of safety signal.  
97
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Section 9.3, Populations for Analyses, Table 11, Analysis Sets:  
Note: Intercurrent medical conditions that may lead to elimination from the PPS are defined as confirmed 
immunodeficiency condition, or development of varicella or herpes zoster in the interval between study intervention 
administration and the collection o f the blood specimen for immunogenicity at Visit  32. 
 
Appendix  1, Abbreviations  and the Glossary of Terms : 
SARS -CoV-2 Severe Acute Respi[INVESTIGATOR_7531] 2  
 
Appendix 4 , Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting : 
b) Solicited systemic events  
The following systemic events will be solicited for children 12 to 15 months of age : 
• Fever  
• Varicella -like rash  (including injection site varicella -like rash)  
 
The maximum intensity of administration site redness/swelling/fever/varicella -like rash will be 
scored as follows : 
 Redness/swelling  Varicella -like rash * Fever† 
0 None  None  < 38.0°C (100.4°F) -Temperature will be 
analyzed  
in 0.5°C  ≥ 38.0°C (100.4°F) - ≤ 39.0°C 
(102.2°F)  
 increments from ≥ > 39.0°C (102.2°F) - ≤ 
39.5°C (103.1°F) 38°C (≥ 100.4°F) . 
Grade 3 fever is defined as  > 39.5°C. 
(103.1°F)  1 > 0 - ≤ 5 mm  1-5025 lesions  
2 > 5 - ≤ 20 mm  5126-[ZIP_CODE] lesions  
3 > 20 mm  >≥ [ZIP_CODE] lesions  
* Including injection site varicella -like rash  
† Temperature will be analyzed in 0.5°C increments from ≥ 38.0°C (≥ 100.4°F).  
 
Events Requiring Expedited Reporting to IQVIA : 
SAE(s) throughout the study  
• Once an the investigator or designee become aware that study participant(s) have experienced an  SAE  has 
occurred in a study participant , the investigator or investigator’s designee  designated study staff must 
complete information in the electronic Expedited AE Report in the eCRF  WITHIN 24  HOURS. The repor t 
will always be completed as thoroughly as possible with all available details of the event. The report allows 
to specify that the event is serious or non -serious.  
• Even if the investigator does not have all information regarding an SAE, the report should still be completed 
within 24 hours. Once additional relevant information is received, the report should be updated WITHIN 24 
HOURS. The investigator will always provide an assessment of causality at the time of the initial report.  
• The investigator will be required to confirm the review of the SAE causality by [CONTACT_43078] “reviewed” box in 
the electronic Expedited AE Report within 72 hours of submission of the SAE.  
• Refer to Section  8.3.1  for the details on timeframes for reporting of SAEs.  
98
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Grade 3 unsolicited AE(s) for the first 200 study participants through their Day 43 follow -up: 
• Once the investigator or designee become aware that study participant(s) have experienced a Grade [ADDRESS_348301] complete information in the electronic Expedited AE Report in the eCRF WITHIN 
24 HOURS. The report will always be completed as thoroughly as possible with all available details of the 
event.  
• Even if the investigator does not have all information regarding a Grade [ADDRESS_348302] possibly related to vaccination, the repo rt should still be completed within 24 hours. Once 
additional relevant information is received, the report should be updated WITHIN 24 HOURS. The 
investigator will always provide an assessment of causality at the time of the initial report.  
• The investigato r will be required to confirm the review of the Grade 3 unsolicited AE(s) causality by 
[CONTACT_43078] “reviewed” box in the electronic Expedited AE Report within 72 hours of submission of the 
Grade 3 unsolicited AE(s).  
• Refer to  Section  8.3.1  for the details o n timeframes for reporting of AE(s).  
  
99
CONFIDENTIAL  217212 (VNS 20 -006)  
Protocol Amendment  3.0 
 Appendix  6 Signature [CONTACT_175100]: A phase II, observer -blind, randomized, controlled study to evaluate 
immunogenicity and safety of a varicella vaccine  at various  potencies  compared with Varivax,  as 
a first dose, administered in healthy children in their second year of life . 
PROTOCOL NO:  217212 (VNS 20 -006) 
VERSION:   Protocol  Amendment 3.[ADDRESS_348303] their 
origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and the 
applicable laws and regulations. Acceptance of this document constitutes my agreement that no 
unpublished informat ion contained herein will be published or disclosed without prior written 
approval from [COMPANY_004].  
Instructions to the Investigator: Please SIGN and DATE this signature [CONTACT_3264] . PRINT your name, title, and the name [CONTACT_285167] . Return the signed copy to IQVIA.  
 
I have read this protocol in its entirety and agree to conduct the study accordingly:  
 
 
 
 
Signature [CONTACT_7919]:  __________________________ _ Date: ________ ________  
Printed Name:   __________________________ _ 
Investigator Title:   ___________________________  
 
Name/Address of Center:  ___________________________  
___________________________  
___________________________  
100